Page: 1
Protocol Number: CA204125
IND Number: 100, [ADDRESS_215459] Number 2014-003282-19
Date: 02-Sep-2015
Revised Date: 11-Nov- 2015
Clinical Protocol CA204125
An Open Label, Randomized Phase 2 Trial of Pomalidomide/Dexamethasone With or Without 
Elotuzumab in relapsed and refractory  Multiple My eloma.
Revised Protocol Number: 01
Incorporates Amendment :
02
Study Director/Central Medical Monitor
Suresh Shelat, MD, PhD
Bristol My ers Squibb Company
 
This document is the confidential and proprietary information of Bristol -Myers Squibb 
Company and its global affiliates (BMS). By [CONTACT_52212], you agre e to keep it 
confidential and to use and disclose it solely for the purpose of assessing whether your 
organization will participate in and/or the performance of the proposed BMS -sponsor ed 
study. Any permitted disclosures will be made only on a confidential "need to know" basis 
2.0
930082867

Clinical Protocol CA204125
BMS -901608 elotuzumab
Revised Protocol No.: 01
Date:  11-Nov-2015 2within your organization or to your independent ethics committee(s). Any other use, 
copying, disclosure or dissemination of this information is strictly prohibited unless 
expressly authorized in writing by [CONTACT_20444]. Any supplemental inform ation (eg,amendments) 
that may be added to this document is also confidential and proprietary to BMS and must 
be kept in confidence in the same manner as the contents of this document. Any person 
who receives this document without due authorization from BMS is requested to return it 
to BMS or promptly destroy it. All other rights reserved. References to BMS in this 
protocol may apply to partners to which BMS has transferred obligations, eg,a Contract 
Research Organization (CRO).
Replace all previous versi on(s) of the protocol with this revised protocol and please provide a 
copy  of this revised protocol to all study  personnel under your supervision, and archive the 
previous versions.
2.0
930082867
Clinical Protocol CA204125
BMS -901608 elotuzumab
Revised Protocol No.: 01
Date:  11-Nov-2015 3DOCUMENT HISTORY
Document Date of Issue Summary of Change
Revised 
Protocol 0111-Nov-2015 Incorporates Amendment 02
Amendment 02 11-Nov-2015 Remove the Circu lating Multiple Myeloma Cells (CMMC) assay and 
to replace with Gene Expression Profiling
Clarify wording of pomalidomide risk management program and 
Pomalidomide Pregnancy Risk Prevention Plan throughout
Minor formatting and typographical revisions
Original 
Protocol02-Sep- 2015 Not applicable
2.0
930082867
Clinical Protocol CA204125
BMS -901608 elotuzumab
SYNOPSIS
Clinical Protocol CA204125
Protocol Title:  An Open Label, Randomized Phase 2 Trial of Pomalidomide/Dexamethasone With or Without 
Elotuzumab in relapsed and refractory Multiple Myeloma
Investigational Product(s), Dose and Mode of Adm inistration, Duratio n of Treatment with Investigational 
Product(s): 
See Study Sche ma for details
Control Arm
Pomalidomide: 4 mg PO QD Days 1 -21 of each cycle
Dexamethasone: 
Subjects  years old: 40 mg PO Days (1, 8, 15 and 22) of each cycle
Subjects > 75 years old: 20 mg PO Days (1, 8, 15 and 22) of each cycle
Elotuzumab Arm
Elotuzumab: 
Cycle 1 - 2: 10 mg/kg IV Days 1, 8, 15 and 22 of each cycle
Cycle 3 and beyond: 20mg/kg IV Day 1 of each cycle
Pomalidomide: 4 mg PO QD Days 1 -21 of each cycle
Dexamethasone: Days 1, 8, 15 and 22 of each cycle
Subjects 75 years old: weeks with elotuzumab dosing: 28 mg PO +8 mg IV and 40 mg PO on 
non-elotuzumab dosing weeks
Subjects > 75 years old: weeks with elotuzumab dosing: 8 mg PO + 8 mg IV and 20 m g PO on non -elotuzumab 
dosing weeks
A cycle is defined as 28 days. Treatment with study drug continues until disease progression, unacceptable toxicity 
(adverse event related to study drug), or subject meets other criteria for discontinuation of study drug outlined in 
Section 3.5.
Study Phase:  2
  
 
Prim ary Objec tive:
To compare progression free survival (PFS) betw een treatment arms
Secondary Objectives:
To compare objective response rate betw een treatment arms
To compare overall survival betw een treatment arms
Revised Protocol No.: 01
Date: 11-Nov-2015 4
2.0
930082867

Clinical Protocol CA204125
BMS -901608 elotuzumab
 
 
 
Study Design:
This is a phase 2 multicenter, open -label, randomized study designed to evaluat e the clinical benefit of the 
investigational combination therapy of elotuzumab, pomalidomide, and dexamethasone (E-Pd; the elotuzumab arm) 
when compared to pomalidomide and dexamethasone (Pd; the control arm) in subjects with relapsed and refractory 
multi ple myeloma (rrMM). 
           
1)Number of lines of prior therapy (2 -3 vs. 4) (Appendix 1 for definition of Line of Therapy)
2)ISS stage at study entry (I-II vs. III) ( Appendix 7 for ISS Staging System).
Revised Protocol No.: 01
Date: 11-Nov-2015 5
2.0
930082867

Clinical Protocol CA204125
BMS -901608 elotuzumab
Study Schema
Follow -Up
Follow -up 
every
4 weeks for
tumor 
response
until PD; 
then
survival
follow -up 
every
12 w eeks or 
more 
frequentlyElotuzumab:   20mg/kg IV Day 1 of each cycle
Pom alidomide:   4 mg PO daily (Days 1 -21) of 
each cycle 
Dexamethasone (weeks with Elotuzumab
dosing ): 
28 mg PO + 8 mg IV on day of elotuzumab 
dosing (subjects  75 years) 
8 mg PO + 8mg IV on day of elotuzumab 
dosing (subjects > 75 years) 
Dexamethasone ( weeks without Elotuzumab
dosing ): 
40 mg PO per week(subjects  75 years old) 
20 mg PO per week(subjects > 75 years old)
See Section 4. 5.1.2Pom alidomide:   4 m g PO d aily (Days 1 -21) of 
each cycle. 
Dexamethasone : 
40 mg PO per day (Day s 1, 8, 15, 22) of each 
cycle (subjects 75 years old)
20 mg PO per day (Days 1, 8, 15, 22) of each 
cycle (subjects > 75 years old )Cycle 3 and beyond
114 Subjects
(1:1)Pom alidomide:   4 m g PO daily 
(Day s 1-21) of each cycle. 
Dexamethasone : 
40 mg PO per day (Days 1, 8, 
15, 22) of each cycle (subjects 
75 years old )
20 mg PO per day (Days 1, 8, 
15, 22) of each cycle (subjects 
> 75 years old )
Elotuzumab:    10 m g/kg IV (Days 
1, 8, 15, 22) of each cycle 
Pom alidomide:   4 mg PO daily 
(Day s 1-21) of each cycle. 
Dexamethasone : 
28 mg PO + 8 mg IV on day s
of elotuzumab dosing (subjects 
75years old )
8 mg PO + 8mg IV on day sof 
elotuzumab dosing (subjects 
>75years old)
See Section 4. 5.1.2R
A
N
D
O
M
I
Z
A
T
I
O
NCycle 1 and 2
Control Arm
Elotuzumab
Arm
Revised Protocol No.: 01
Date: 11-Nov-2015 6
2.0
Approved
930082867
2.0
v
Clinical Protocol CA204125
BMS -901608 elotuzumab
Study Population: 
Subjects who are diagnosed with relapsed and refractory multiple myeloma defined as:
1)Must have received 2 prior lines of therapy (See Appendix 1) w hich must have included at least 2 consecutive 
cycles of lenalidomide and a proteosome inhibitor alone or in combination.
2)Documented refractory or relap sed and refractory (R/R) multiple myeloma
3)Refractory (progressed on or within 60 days of treatment) to their last treatment.
4)Subjects must have failed treatment with a proteosome inhibitor and lenalidomide in one of the following ways.
a)“Refractory ” to prot eosom e inhibitor and lenalidomide, and to their last treatment.
b)“Relapsed and refractory” = patients had achieved at least a partial response to previous treatment with 
proteosome inhibitor or lenalidomide, or both, but progressed within [ADDRESS_215460] treatment
Study Drug: includes both Investigational [Medicinal] Products (IP/IMP) and Non-investigational 
[Medicinal] Products (Non -IP/Non -IMP) as listed:
Study Drug for CA204125
Medication Potency IP/Non -IP
Elotuzumab 400mg/vial IP
Pomalidomide Capsules 1 mg, 2 mg, 3 mg and 4 mg Non-IP
Dexamethasone Tablets 2 mg and 4 mg & various strengths Non-IP
Dexamethasone Solution 4 mg/mL, 8 mg/mL & various strengths Non-IP
Study Assessments:  Tum or response assessment by [CONTACT_182457] (Appendix 6) will be evaluated 
during the trial for all randomized subjects. The prim ary endpoint of PFS will be based on the investigator’s 
assessment
Statistical Considerations: 
  
 
 
 
  
 
 
 
 
 
 
 
 
 
 
Revised Protocol No.: 01
Date: 11-Nov-2015 7
2.0
930082867

Clinical Protocol CA204125
BMS -901608 elotuzumab
 
 
 
  
 
Endpoints:   
Prim ary Endpoint:
PFS will be defined as the time, in months, from random ization to the date of the first documented tumor 
progression or death due to any cause. Clinical deterioratio n will not be considered progression. A subject who 
neither progresses nor dies will be censored on the date of their last tumor assessment. A subject who does not have 
any post-baseline tumor assessments and who has not died will be censored on the date at which they were 
randomized.
Secondary Endpoint:
1)Objective response rate is defined as the proportion of random ized subjects who achieve a best response of 
partial response (PR) or better using the criteria in Appendix 6 as per investigator’s assessment.
2)Overall survival is defined as the time from randomization to the date of death from any cause. If a subject has 
not died, their survival time will be censored at the date of last contact (“last known alive date”). A subject will 
be censored at the date o f randomization if they were randomized but had no follow -up.
  
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
Revised Protocol No.: 01
Date: 11-Nov-2015 8
2.0
930082867

TABLE OF CONTENTS 
TITLE PAGE ................................................................................................................ 
DOCUMENT HISTORY .............................................................................................. SYNOPSIS .................................................................................................................... TABLE OF CONTENTS .............................................................................................. 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
1.2 Research Hypothesis ......................................................................................... 1.3 Objectives(s) ..................................................................................................... 
1.3.[ADDRESS_215461]/Independent Ethics Committee ............................. 2.[ADDRESS_215462] Study Access to Therapy ........................................................................... 3.3 Study Population ............................................................................................... 
3.3.1 Inclusion Criteria ..................................................................................... 3.3.2 Exclusion Criteria .................................................................................... 1
3
4
9
13
13
13
13
13
13
15
18
19
20
21
21
23
23
25
25
27
28
2828
28
29
29
29
30
30
30
31
33
34
34
34
34
35
35
37
37
37
37
39Clinical Protocol
BMS-901608CA204125
elotuzumab
Revised Protocol No.: 01Date: 11-Nov-2015 9
2.0
930082867

3.3.3 Women of Childbearing Potential ........................................................... 
3.4 Concomitant Treatments ................................................................................... 
3.4.1 Required ................................................................................................... 
3.4.2 Permitted at Investigator’s Discretion ..................................................... 3.4.3 Prohibited and/or Restricted Treatments................................................. 3.4.[ADDRESS_215463] ............................................... 
4.5.1 Treatment with Study Drugs .................................................................... 
[IP_ADDRESS] Pomalidomide ................................................................................. [IP_ADDRESS] Dexamethasone ............................................................................... [IP_ADDRESS] Elotuzumab ..................................................................................... [IP_ADDRESS] Elotuzumab Premedication Regimen in Subjects Without a Prior 
Infusion Reaction .................................................................................. 
[IP_ADDRESS] Elotuzumab Premedication Regimen in Subjects With a Prior 
Infusion Reaction .................................................................................. 
4.5.2 Guidelines for Elotuzumab Infusion in Subjects with Infusion Reactions
..................................................................................................................... [IP_ADDRESS] Grade 1 Infusion Reaction .............................................................. [IP_ADDRESS] Grade /g149 2 Infusion Reaction ........................................................... [IP_ADDRESS] Grade 4 Infusion Reaction .............................................................. 
4.5.3 Dose Delay, Interruption, or Discontinuation, All Subjects .................... 
[IP_ADDRESS] Elotuzumab ..................................................................................... [IP_ADDRESS] Dexamethasone ............................................................................... [IP_ADDRESS] Pomalidomide ................................................................................. 
4.5.4 Recommended Dose Reduction ................................................................ 
[IP_ADDRESS] Elotuzumab ..................................................................................... [IP_ADDRESS] Dexamethasone ............................................................................... [IP_ADDRESS] Pomalidomide ................................................................................. 
4.6 Blinding/Unblinding ......................................................................................... 4.7 Treatment Compliance ...................................................................................... 4.8 Destruction and Return of Study Drug ............................................................. 
4.8.1 Destruction of Study Drug ....................................................................... 
4.9 Return of Study Drug ........................................................................................ 41
41
41
42
42
43
43
44
44
45
46
48
48
48
48
49
49
50
50
50
50
50
51
51
52
52
54
54
54
54
55
55
55
55
56
56
56
58
58
58
59
59
59Clinical Protocol
BMS-901608CA204125
elotuzumab
Revised Protocol No.: 01Date: 11-Nov-2015 10
2.0
930082867

4.10 Retained Samples for Bioavailability / Bioequivalence ................................. 
5 STUDY ASSESSMENTS AND PROCEDURES ..................................................... 
5.1 Flow Chart/Time and Events Schedule ............................................................. 
5.1.1 Retesting During Screening Period ......................................................... 
5.2 Study Materials ................................................................................................. 
5.3 Safety Assessments ........................................................................................... 
5.3.1 Imaging Assessment for the Study............................................................ 5.3.2 Vital Signs, Physical Measurements, and Physical Examination ............ 5.3.3 Performance Status .................................................................................. 5.3.4 Cardiac Assessments ................................................................................ 5.3.5 Laboratory Assessments for Safety .......................................................... 
5.4 Efficacy Assessments ........................................................................................ 
5.4.1 Primary Efficacy Assessment ................................................................... 5.4.2 Laboratory Assessments for Myeloma ..................................................... 5.4.3 Imaging Assessments for Myeloma .......................................................... 
[IP_ADDRESS] Skeletal Survey ................................................................................ [IP_ADDRESS] Assessment of Extramedullary Plasmacytoma................................ 
5.4.4 Definitions of Response and Progression Criteria .................................. 
5.5 Pharmacokinetic Assessments .......................................................................... 
5.5.1 Anti-Drug Antibody (ADA)Assessments .................................................. 5.5.2 Pharmacogenomic/Pharmacogenetic Assessments ................................. 
 
 
 
 
 
 
 
 
[ADDRESS_215464] Result Abnormalities .............................................................. 
6.4 Pregnancy .......................................................................................................... 6.5 Overdose ........................................................................................................... 6.6 Potential Drug Induced Liver Injury (DILI) ..................................................... 6.7 Other Safety Considerations ............................................................................. 
7 DATA MONITORING COMMITTEE ..................................................................... 8 STATISTICAL CONSIDERATIONS....................................................................... 
8.1 Sample Size Determination ............................................................................... 8.2 Populations for Analyses .................................................................................. 8.3 Endpoints .......................................................................................................... 
8.3.1 Primary Endpoint(s) ................................................................................ 
[IP_ADDRESS] Primary definition of PFS ............................................................... 59
60
60
76
76
76
77
77
77
77
77
79
79
79
81
81
81
82
82
83
84
84
84
85
85
85
87
8787
87
87
89
89
90
90
90
91
91
91
92
92
92
92
93
93
93Clinical Protocol
BMS-901608CA204125
elotuzumab
Revised Protocol No.: 01Date: 11-Nov-2015 11
2.0
930082867

[IP_ADDRESS] Secondary Definition of PFS: ......................................................... 
8.3.2 Secondary Endpoint(s) ............................................................................. 
[IP_ADDRESS] Objective response rate................................................................... 
[IP_ADDRESS] Overall survival .............................................................................. 
 
 
 
8.4 Analyses ............................................................................................................ 
8.4.1 Demographics and Baseline Characteristics........................................... 8.4.2 Efficacy Analyses ..................................................................................... 
[IP_ADDRESS] Primary Efficacy Analysis: PFS ..................................................... [IP_ADDRESS] Secondary Efficacy Analysis ........................................................... 
8.4.3 Safety Analyses......................................................................................... 8.4.4 Pharmacokinetic Analyses ....................................................................... 8.4.5 Biomarker Analyses ................................................................................. 8.4.6 Outcomes Research Analyses .................................................................. 
[IP_ADDRESS] Analysis of PRO Data ..................................................................... 
8.4.7 Other Analyses ......................................................................................... 
8.5 Interim Analyses ............................................................................................... 
9 STUDY MANAGEMENT ........................................................................................ 
9.1 Compliance ....................................................................................................... 
9.1.1 Compliance with the Protocol and Protocol Revisions ........................... 9.1.2 Monitoring ............................................................................................... 
[IP_ADDRESS] Source Documentation .................................................................... 
9.1.[ADDRESS_215465] OF ABBREVIATIONS .................................................................................. 12 REFERENCES ........................................................................................................ APPENDIX 1 DEFINITION OF LINES OF THERAPY ............................................ APPENDIX 2 PERFORMANCE STATUS SCALES ................................................. APPENDIX 3 M. D. ANDERSON SYMPTOM INVENTORY - MULTIPLE 
MYELOMA (MDASI - MM) ................................................................................. 
APPENDIX 4 EUROPEAN QUALITY OF LIFE - 5 DIMENSIONS (EQ-5D) ......... APPENDIX 5 PREPARATION AND ADMINISTRATION OF ELOTUZUMAB ... APPENDIX 6 DEFINITIONS OF RESPONSE AND PROGRESSION CRITERIA 
(MODIFIED FROM IMWG) ................................................................................. 
APPENDIX 7 THE INTERNATIONAL STAGING SYSTEM (ISS) FOR MULTIPLE 
MYELOMA ............................................................................................................ 
APPENDIX 8 POMALIDOMIDE PREGNANCY RISK PREVENTION PLAN ...... 
 93
94
94
94
94
94
94
94
94
94
94
95
95
95
95
96
96
96
96
97
97
97
97
98
98
98
98
9899
99
101
102
105
109
110
111
113
115
119
121
122Clinical Protocol
BMS-901608CA204125
elotuzumab
Revised Protocol No.: 01Date: 11-Nov-2015 12
2.0
930082867

Clinical Protocol CA204125
BMS -901608 elotuzumab
1 INTRODUCTION AND STUDY RA TIONA LE
 
 
 
 
i 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revised Protocol No.: 01
Date: 11-Nov-2015 13
2.0
930082867

Clinical Protocol CA204125
BMS -901608 elotuzumab
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
Revised Protocol No.: 01
Date: 11-Nov-2015 14
2.0
930082867

Clinical Protocol CA204125
BMS -901608 elotuzumab
 
  
 
 
 
 
 
Revised Protocol No.: 01
Date: 11-Nov-2015 15
2.0
930082867

Clinical Protocol CA204125
BMS -901608 elotuzumab
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revised Protocol No.: 01
Date: 11-Nov-2015 16
2.0
930082867

Clinical Protocol CA204125
BMS -901608 elotuzumab
 
 
 
 
 
 Protocol No.: 01
Date: 11-Nov-2015 17
2.0
930082867

Clinical Protocol CA204125
BMS -901608 elotuzumab
Revised Protocol No.: 01
Date: 11-Nov-2015 18
2.0
930082867

Clinical Protocol CA204125
BMS -901608 elotuzumab
Revised Protocol No.: 01
Date: 11-Nov-2015 19
2.0
930082867

Clinical Protocol CA204125
BMS -901608 elotuzumab
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revised Protocol No.: 01
Date: 11-Nov-2015 20
2.0
930082867

Clinical Protocol CA204125
BMS -901608 elotuzumab
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
  
 
 
Revised Protocol No.: 01
Date: 11-Nov-2015 21
2.0
930082867

Clinical Protocol CA204125
BMS -901608 elotuzumab
  
Revised Protocol No.: 01
Date: 11-Nov-2015 22
2.0
930082867

Clinical Protocol CA204125
BMS -901608 elotuzumab
 
 
 
 
 
 
 
 
   
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revised Protocol No.: 01
Date: 11-Nov-2015 23
2.0
930082867

Clinical Protocol CA204125
BMS -901608 elotuzumab
  
 
 
 
 
 
 
 
 
 
2.0
930082867

Clinical Protocol CA204125
BMS -901608 elotuzumab
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
Revised Protocol No.: 01
Date: 11-Nov-2015 25
2.0
930082867

Clinical Protocol CA204125
BMS -901608 elotuzumab
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revised Protocol No.: 01
Date: 11-Nov-2015 26
2.0
930082867

Clinical Protocol CA204125
BMS -901608 elotuzumab
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revised Protocol No.: 01
Date: 11-Nov-2015 27
2.0
930082867

Clinical Protocol CA204125
BMS -901608 elotuzumab
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.3 Objectives(s)
1.3.1 Primary Objectives
To compare progression free survival (PFS) between treatment arms.
1.3.2 Secondary Objectives
To compare objective response rate between treatment arms
To compare overall survival between treatment arms 
Revised Protocol No.: 01
Date: 11-Nov-2015 28
2.0
930082867

Clinical Protocol CA204125
BMS -901608 elotuzumab
 
 
 
 
 
 
 
 
 
  
 
   
  
 
 
 
 
 
 
 
 
Revised Protocol No.: 01
Date: 11-Nov-2015 29
2.0
930082867

Clinical Protocol CA204125
BMS -901608 elotuzumab
 
 
 
 
 
 
 
 
 
 
   
 
 
  
 
 
 
 
        
 
 
 
  
 
 
 
 
 
 
Revised Protocol No.: 01
Date: 11-Nov-2015 30
2.0
930082867

Clinical Protocol CA204125
BMS -901608 elotuzumab
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revised Protocol No.: 01
Date: 11-Nov-2015 31
2.0
930082867

Clinical Protocol CA204125
BMS -901608 elotuzumab
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
  
 
 
 
 
 
 
 
 
 
 
Revised Protocol No.: 01
Date: 11-Nov-2015 32
2.0
930082867

Clinical Protocol CA204125
BMS -901608 elotuzumab
combination with Ld at the accelerated infusion rate over approximately  60 min (a maximum 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revised Protocol No.: 01
Date: 11-Nov-2015 33
2.0
930082867

Clinical Protocol CA204125
BMS -901608 elotuzumab
 
 
 
2 ETHICA L CONSIDERA TIONS
2.1 Good Clinical Practice
This study  will be conducted in accordance with Good Clinical Practice (GCP), as defined by  [CONTACT_20417] (ICH) andin accordance with the ethical principles 
underly ing European Union Directive 2001/20/EC and the [LOCATION_002] Code of Federal 
Regulations, Title 21, Part 50 (21CFR50).
The study  will be conducted in compliance with the protocol. The protocol and any amendments 
and the subject informed consent will receive Institutional Review Board/I ndependent Ethics 
Committee (I RB/IEC) approval/favorable opi[INVESTIGATOR_52194] .
All potential serious breaches must be reported to BMS immediatel y. A serious breach is a 
breach of the conditions and principles of GCP in connection with the study  or the protocol, 
which is likely to affect, to a significant degree, the safet y or physical or mental integrity  of the 
subjects of the study  or the scientific value o f the study .
Personnel involved in conducting this study  will be qualified by [CONTACT_8640], training, and 
experience to perform their respective tasks.
This study  will not use the services of study  personnel where sanctions have been invoked or 
where there has been scientific misconduct or fraud (eg, loss of medical licensure, debarment). 
2.[ADDRESS_215466]/Independent Ethics Committee 
Before study  initiation, the investigator must have written and dated approval/favorable opi[INVESTIGATOR_20291]/IEC for the protocol, consent form, subject recruitment materials 
(eg,advertisements), and any other written information to be provided to subjects. The 
investigator or BMS should also provide the IRB/IEC with a copy of the Investigator Brochure 
or product labe ling information to be provided to subjects and any  updates. 
The investigator or BMS should provide the IRB/IEC with reports, updates and other 
information (eg, expedited safet y reports, amendments, and administrative letters) according to 
regulatory  requ irements or institution procedures.
2.[ADDRESS_215467] ensure that subjects are clearl y and fully  informed about the purpose, potential 
risks, and other critical issues regarding clinical studies in which they volunteer to participate. 
Insituations where consent cannot be given to subjects, their legally  acceptable representatives 
(as per country  guidelines) are clearl y and fully informed about the purpose, potential risks, and 
other critical issues regarding clinical studies in which the subject volunteers to participate. 
Revised Protocol No.: 01
Date: 11-Nov-2015 34
2.0
930082867

Clinical Protocol CA204125
BMS -901608 elotuzumab
BMS will provide the investigator with an appropriate (ie, Global or Local) sample informed 
consent form which will include all elements required by [CONTACT_12212], GCP and applicable regulatory 
requirements. The sample informed consent form will adhere to the ethical principles that have 
their origin in the Declaration of Helsinki.
Investigators must:
Provide a copy of the consent form and written information about the study  in the language in 
which the subject is most proficient prior to clinical study  participation. The language must be 
non-technical and easil y understood. 
Allow time necessary  for subject or subject's legally  acceptable representative to inquire about 
the details of the study .
Obtain an informed consent signed and personally  dated by [CONTACT_29159]'s legall y 
acceptable representative and by  [CONTACT_28490]. 
Obtain the IRB/IEC’s written approval/favorable opi[INVESTIGATOR_82705], prior to the beginning of the study , and 
after an y revisions are completed for new information.
If informed consent is initially  given by a  subject’s legall y acceptable representative or legal 
guardian, and the subject subsequently  becomes capable of making and communicating his or 
her informed consent during the stud y, consent must additionally be obtained from the subject.
Revise the informed consent whenever important new information becomes available that is 
relevant to the subject's consent. The investigator, or a person designated by [CONTACT_093], 
should fully  inform the subject or the subject's legally  acceptable representative or legal 
guardian, of all pertinent aspects of the study  and of any  new in formation relevant to the subject's 
willingness to continue participation in the study . This communication should be documented. 
The confidentiality  of records that could identify  subjects must be protected, respecting the 
privacy  and confidentiality  rules applicable to regulatory  requirements, the subjects' signed ICF 
and, in the US, the subjects’ signed HIPAA Authorization.
The consent form must also include a statement that BMS and regulatory  authorities have direct 
access to subject records. 
The right s, safet y, and well -being of the study  subjects are the most important considerations and 
should prevail over interests of science and society.
 
 
 
A cycle is defined as 28 days.
Revised Protocol No.: 01
Date: 11-Nov-2015 35
2.0
930082867

Clinical Protocol CA204125
BMS -901608 elotuzumab
Table 3.1-1: Study Design Schematic
114 Subjects
(1:1)R
A
N
D
O
M
I
Z
A
T
I
O
NControl Arm
Elotuzumab
ArmPom alidomide:   4 m g PO daily 
(Day s 1-21) of each cycle. 
Dexamethasone : 
40 mg PO per day (Days 1, 8, 
15, 22) of each cycle (subjects ≤ 
75 years old )
20 mg PO per day (Days 1, 8, 
15, 22) of each cycle (subjects > 
75 years old )
Elotuzumab:    10 m g/kg IV (Days 1, 
8, 15, 22) of each cycle 
Pom alidomide:   4 mg PO daily (Days 
1-21) of each cycle. 
Dexamethasone : 
28 mg PO + 8 mg IV on days of 
elotuzumab dosing (subjects ≤ 75 
years old) 
8 mg PO + 8mg IV on days of 
elotuzumab dosing (subjects > 75 
years old) 
See Section 4.5.1.2Cycle 1 and 2
Follow -Up
Follow -up 
every
4 weeks for
tumor response
until PD; 
then
survival
follow -up
every
12 w eeks
or more 
frequentlyElotuzumab:   20 m g/kg IV Day 1 of each cycle.
Pom alidomide:   4 m g PO daily (Days 1 -21) of 
each cycle. 
Dexamethasone (weeks with Elotuzumab 
dosing) : 
28 mg PO + 8 mg IV on days of elotuzumab 
dosing (subjects ≤ 75 years) 
8 mg PO + 8mg IV on days of elotuzumab 
dosing (subjects > 75 years) 
Dexam ethasone (weeks without Elotuzumab 
dosing) : 
40 mg PO per w eek for subjects 75 years old. 
20 mg PO per w eek for subjects > 75 years old. 
See Section 4.5.1.2Pom alidomide:   4 m g PO d aily (Days 1 -21) of 
each cycle. 
Dexamethasone : 
40 mg PO per day (Day s 1, 8, 15, 22) of each 
cycle (subjects ≤ 75 years old )
20 mg PO per day (Days 1, 8, 15, 22) of each 
cycle (subjects > 75 years old )Cycle 3 and beyond
Revised Protocol No.: 01
Date: 11-Nov-[ADDRESS_215468] Study  Access to Therapy
At the conclusion of the study , subjects who continue to demonstrate clinical benefit will be 
eligible to receive study drug. Study  drug will be provided via an extension of the study , a 
rollover study  requiring approval by [CONTACT_52228] y and ethics committee or 
through another mechanism at the discretion of B MS. BMS reserves the right to terminate access 
to study  drug if any of the following occur: a) the marketing application is rejected by 
[CONTACT_20429] ; b) the study  is terminated due to safety  concerns; c) the subject can 
obtain medication from a government sponsored or private health program; or d) therapeutic 
alternatives become available in the local market.
3.[ADDRESS_215469] be met.
3.3.1 Inclusion Criteria
1) Signed Written Informed Consent
a)Subject is, in the investigator’s opi[INVESTIGATOR_1649], willing and able to comply  with the protocol 
requirements.
b) Subject has given voluntary  written informed consent before performance of any 
study -related procedure not part of normal medical care, with the understanding that 
consent may be withdrawn by [CONTACT_182458].
2) Target Population
a)Must have received 2 prior lines of therap y (See Appendix 1) which must have 
included at least 2 consecutive cycles of lenalid omide and a proteosome inhibitor alone 
or in combination.
b)Documented refractory  or relapsed and refractory  (R/R) multiple my eloma
c)Refractory  (progressed on or within 60 day s of treatment) to their lasttreatment.
d)Subjects must have failed treatment with a proteosome inhibitor and lenalidomide in one 
of the following way s41.
i)“Refractory ” to proteosome inhibitor and lenalidomide, and to their last treatment.
ii)“Relapsed and refractory ”= patients had achieved at least a partial response to 
previous treatment with proteosome inhibitor or lenalidomide, or both, but progressed 
within [ADDRESS_215470] treatment.
Revised Protocol No.: 01
Date: 11-Nov-2015 37
2.0
930082867

Clinical Protocol CA204125
BMS -901608 elotuzumab
e)Measurable disease at screening, based on central lab results, defined as one or more of 
the following:
i)Serum IgG, IgA, or IgM M -protein  0.5 g/dL (5 g/L).
ii)Urine M -Protein  200 mg (0.2 g) excreted in a 24 -hour collection sample
iii)Involved serum free light chain (sFLC) 100 mg/L (10 mg/dL) provided the FLC 
ratio is abnormal.
f)Eastern Cooperative Oncology  Group (ECOG) performance status  2.
3)Age and Reproductive Status
a)Males and Females at least 18 y ears or legal age of consent per local regulations .
b)Women of childbearing potential (WOCBP) must have two negati ve serum or urine 
pregnancy  tests (minimum sensitivity  25 mIU/mL or equivalent units of HCG). One 
10-14 days prior to start of the study  drug and one 24 hours prior to the start of study  
drug. See Section 3.3.3 for the definition of WOCBP.
c)Women must not b e breastfeeding .
d)WOCBP must agree to follow instructions for method(s) of contraception for [ADDRESS_215471]-treatment completion.
e)Males who are sexually  active with WOCBP must alway s use a latex or synthetic 
condom during any sexual contact [CONTACT_182459], even if they 
have undergone a successful vasectomy . They  must also agree to follow instructions for 
method(s) of contraception for [ADDRESS_215472]-treatment 
completion.
f)Male patients must not donate sperm, for up to [ADDRESS_215473] treatment completion.
g)Azoospermic males and WOCBP who are not heterosexually  active are exempt from 
contraceptive requirements. However they must still undergo pregnancy  testing as 
described in this section.
h)All Subjects must not donate blood for [ADDRESS_215474] treatment c ompletion .
i)All subjects must be willing and able to comply  with the local pomalidomide risk 
management program or the Pomalidomide Pregnancy  Risk Prevention Plan.
j)All subjects must agree not share study  medication .
Investigators shall counsel WOCBP and male subjects who are sexually  active with WOCBP on 
the importance of pregnancy  prevention and the implications of an unexpected pregnancy  
Investigators shall advise WOCBP and male subjects who are sexually  active with WOCBP on 
the use of highl y effective methods of contraception. Highl y effective methods of contraception 
have a failure rate of < 1% when used consistently  and correctl y.
At a minimum, subjects must agree to the use of two methods of contraception, with one method 
being highl y effective and the other method being either highl y effective or less effective as 
listed in the informed consent document.
Revised Protocol No.: 01
Date: 11-Nov-2015 38
2.0
930082867
Clinical Protocol CA204125
BMS -901608 elotuzumab
3.3.2 Exclusion Criteria
1)Target Disease Exceptions
a)Subjects with solitary  bone or extramedullary  plasmacy toma as the only evidence of 
plasma cell d yscrasi a.
b)Subjects with monoclonal gammopath y of undetermined significance (MGUS), 
smoldering multiple myeloma (SMM), amyloidosis, Waldenstrom’s macroglobulinemia, 
or POEMS syndrome (plasma cell dyscrasia with poly neuropathy , organomegal y, 
endocrinopath y, monocl onal protein, and skin changes) 
c)Subjects with active plasma cell leukemia (defined as either 20% of peripheral blood 
white blood cell count comprised of plasma/CD138+ cells or an absolute plasma cell 
count of 2 x 109/L)
2)Medical History and Concurrent Dise ases
a)Any uncontrolled or severe cardiovascular or pulmonary  disease determined by [CONTACT_1275], including:
i)NYHA functional classification III or IV, congestive heart failure, unstable or poorl y 
controlled angina, hypertension, arrhythmia, or myocardial infarction in the past 
12months.
b) Active infection that requires parenteral anti- infective treatment > 14 day s
c)Unable to tolerate thromboembolic prophy laxis while on the study
d)Hypersensitivity  reaction to prior I MiD (thalidomide or lenalidomide) 
e)Grade 2 peripheral neuropathy  (per NCI CTCAE v3.0)
f)Known active hepatitis A, B, or C
g)Known HIV infection
h)Gastrointestinal disease that may  significantly  alter the absorption of pomalidomide
i)Prior or concurrent malignancy , except for the following:
i)Adequatel y treated basal cell or squamous cell skin cancer.
ii)Any cancer (other than in-situ) from which the subject has been disease free for 
> 3years prior to study  entry .
3) Prior Therapy or Surgery
a)Prior treatment with pomalidomide.
b)Prior participation in an elotuzumab clinical trial regardless of treatment assignment.
c)Use of any anti-myeloma drug therapy , within 14 days of the initiation of study  drug 
treatment or use of any experimental drug therapy or plasmapheresis within 28 day s (or 5
half-lives ) whichever is longer of the initiation of study  drug treatment (includes 
dexamethasone). Bisphosphonate use permitted.
d)Treatment with melphalan or monoclonal antibodies within [ADDRESS_215475] dose of 
study  drug
e)Prior autologous stem cell transplant within [ADDRESS_215476] dose of study  drug.
f)Prior allogeneic stem cell transplant except subjects who have completed the stem cell 
transplant > [ADDRESS_215477] disease, and are not on topi[INVESTIGATOR_182441] y
Revised Protocol No.: 01
Date: 11-Nov-2015 39
2.0
930082867
Clinical Protocol CA204125
BMS -901608 elotuzumab
g)Treatment with corticosteroids within [ADDRESS_215478] dose of study  drug, except for 
the equivalent of 10 mg prednisone per day or corticosteroids with minimal to no 
systemic absorption (ie, topi[INVESTIGATOR_180123]) or for short course (4 days) of 
40mg dexamethasone or equivalent for emergency  use (baseline M proteins must be 
drawn after this short cou rse and prior to randomization).
h)Major cardiac surgery  within [ADDRESS_215479] dose of study  drug; all other ma jor 
surgery  within [ADDRESS_215480] dose of study  drug. (Kyphoplasty  is not 
considered major surgery ); subjects should have been fully  recovered from any surgical 
related toxicities.
4) Physical and Laboratory Test Findings
a)Corrected serum calcium 11.5 mg/dl (see equation in Section 5.4.2) within 2 weeks of 
randomization (despi[INVESTIGATOR_182442] a short course of steroids, 
bisphosphonates, hy dration, calcitonin).
b)Absolute neutrophil count < 1 x 10⁹/L(1000/uL) . No growth factors allowed within [ADDRESS_215481] dose of study  drug. No pegy lated growth factors within 3 weeks of 
randomization.
c)Platelets < 75 x 109/L (75,000/uL ) (< 30 x 109/L if 50% of bone marrow nucleated cells 
were plasma cells). Qualify ing laboratory  value must occur at most recent measurement 
prior to randomization and must be no more than 14 days prior to randomization . No 
transfusions are allowed within 72 hours prior to qualify ing laboratory  value .
d)Hemoglobin < 80g/L(8g/dL) .Qualify ing lab
oratory  value must occur at most recent 
measurement prior to randomization and must be no more than 14 days prior to 
randomization. No transfusions are allowed within 72 hours prior to qualify ing laboratory  
value
e)Creatinine clearance < 45 ml/min according to the Cockroft -Gault formula.
1)Female CrCl = (140 -age in y ears) x body  weight in kg x 0.85
2)72 x serum creatinine in mg/dl
3)Male CrCl = (140 -age in y ears) x body  weight in kg x 1.00
4)72 x serum creatinine in mg/dl
Qualify ing serum creatinine value must oc cur at most recent measurement prior to randomization
and must be no more than 14 day s prior to randomization .
f)Total bilirubin [ADDRESS_215482]
i)Subjects with known Gilbert’s syndrome must NOT have a total bilirubin [ADDRESS_215483] bilirubin within the institutional limit of normal
g)Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) [ADDRESS_215484]
5)Other Exclusion Criteria
a)Known hypersensitivity  or intolerance to lenalidomide, dexamethasone, or any  excipi[INVESTIGATOR_182443], formulation or recombinant protein.
Revised Protocol No.: 01
Date: 11-Nov-2015 40
2.0
930082867
Clinical Protocol CA204125
BMS -901608 elotuzumab
b)Sexually  active fertile men not using 2 forms of effective birth control if their partners are 
WOCBP. 
c)Prisoners or subjects who are involuntaril y incarcerated.
d)Subjects who are compulsorily  detained for treatment of either a psychiatric or physical 
(eg, infectious disease) illness.
Eligibility  criteria for this study  have been carefully  considered to ensure the safet y of the study 
subjects and that the results of the study  can be used. It is imperative that subjects fully meet all 
eligibility  criteria.
3.3.3 Women of Childbearing Potential
Women of childbearing potential (WOCBP), as defined by [CONTACT_182460], must also include 
all females who are menstruating, amenorrheic from previous medical treatments, under 50 years 
of age, and/or perimenopausal, and do not qualify for the category  “females not of reproductive 
potential ”.
Females not of reproductive potential, as defined by [CONTACT_182461] ,include females who have been 
in natural menopause for at least [ADDRESS_215485] had a hy sterectom y and/or 
bilateral oophorectomy .
Females treated with hormo ne replacement therapy , (HRT) are likely  to have artificiall y 
suppressed FSH levels and may require a washout period in order to obtain a physiologic FSH 
level. The duration of the washout period is a function of the type of HRT used. The duration of 
the washout period below are suggested guidelines and the investigators should use their 
judgment in checking serum FSH levels. If the serum FSH level is >40 mIU/ml at any time 
during the washout period, the woman can be considered postmenopausal:
1 week minim um for vaginal hormonal products (rings, creams, gels)
4 week minimum for transdermal products
[ADDRESS_215486] receive pre-medications (Sections [IP_ADDRESS] and [IP_ADDRESS]) prior to each dose of 
elotuzumab.
Revised Protocol No.: 01
Date: 11-Nov-2015 41
2.0
930082867
Clinical Protocol CA204125
BMS -901608 elotuzumab
3.4.2 Permitted at Investigator’s Discretion
IV corticosteroids, diphenhy dramine, or hydroxyzine, acetaminophen/ paracetamol, 
H2inhibitors (ie, cimetidine), leukotriene inhibitors (montelukast sodium) for the management 
of infusion reactions. Additional supportive measures should be provided as indicated including:
oxygen inhalation
epi[INVESTIGATOR_238]
bronchodilators
oral antiviral and antimicrobial proph ylaxis
anti-emetics
bisphosphonates
Per the ASCO [ADDRESS_215487] stable disease, although further use is at 
the discretion of the investigator.
Routine clinical practice for monitoring and prevention of osteonecrosis of the jaw 
(ie,comprehensive dental exam, treating active oral infections, eliminating sites of high risks for 
oral infection, excellent oral hygiene and avoiding invasive dental procedures while on 
treatment) must be followed.
Erythropoietin (EPO) or erythropoiesis stimulating agents (prior and ongoing use according 
to the package insert and institutional guidelines)
Red blood cel l or platelet transfusion
Prophy lactic administration of G-CSF for neutropenic subjects or therapeutic use in subjects 
with serious neutropenic complications (such as tissue infection, sepsis syndrome or fungal 
infection) may be considered at the investiga tor's discretion, consistent with American 
Society  of Clinical Oncology guidelines (American Society  of Clinical Oncology  2006).
3.4.3 Prohibited and/or Restricted Treatments
Any systemic, anti-myeloma therapy  other than pomalidomide, dexamethasone, and elotuzu mab 
are prohibited while on study  therap y. Concomitant steroids, other than weekl y dexamethasone 
Section 4.5.1 or steroids allowed (as defined in eligibility  criteria) are prohibited unless used to 
treat an adverse event. Guidelines for selection and use of other concomitant medications should 
be derived from the pomalidomide and dexamethasone prescribing information. 
Avoid co-administration of pomalidomide with strong inhibitors of CYP1A2 unless medically 
necessary .Co-administration of pomalidomide with drugs that are strong inhibitors of CYP1A2 
(eg,ciprofloxacin, enoxacin and fluvoxamine) and CYP3A4/5 (eg,ketoconazole) or P-gp could 
increase pomalidomide exposure and should be avoided, unless medicall y necessary,43,44. 
Revised Protocol No.: 01
Date: 11-Nov-2015 42
2.0
930082867
Clinical Protocol CA204125
BMS -901608 elotuzumab
Other than study  medications, administration of any therapeutic or diagnostic investigational 
agent (for an y indication) is prohibited while on study  therapy  without prior Sponsor approval.
3.4.[ADDRESS_215488] develops a definite increase in the size of existi ng bone lesions or soft tissue 
plasmacy tomas that meets the criteri a for disease progression (Appendix 6),treatment must be 
discontinued for progressive disease regardless of whether radiation therap y is initiated
(Section 3.5).
Kyphoplast y, vertebroplast y, or emergency  orthopedic surgery is permitted.
3.[ADDRESS_215489] (and non-investigational product at the 
discretion of the investigator) for an y of the f ollowing reasons:
Withdrawal of informed consent (subject’s decision to withdraw for any  reason)
Any clinical adverse event (AE), laboratory  abnormality  or intercurrent illness which, in the 
opi[INVESTIGATOR_871], indicates that continued participati on in the study  is not in the 
best interest of the subject.
Pregnancy  (Subjects must discontinue elotuzumab and pomalidomide).
Termination of the stud y by [CONTACT_414] -Myers Squibb (BMS).
Loss of abilit y to freely provide consent through imprisonment or involuntarily  incarceration 
for treatment of either a psy chiatric or ph ysical (eg, infectious disease) illness.
Progressive Disease (Appendix 6)
Subjects who receive any non-protocol specified systemic anti-myeloma therap y before 
documented progression will be discontinued from all study  treatment (including 
pomalidomide/dexamethasone); however, tumor assessments will continue at 4 week 
intervals until documented progression.
Subjects experiencing a Grade [ADDRESS_215490] discontinue elotuzumab. Subjects 
may continue pomalidomide and dexamethasone treatment. Refer to Section [IP_ADDRESS].
Subjects experiencing angioedema, Grade [ADDRESS_215491] 
discontinue pomalidomide. Subjects in the elotuzumab arm may continue elotuzumab and 
dexamethasone.
Subjects experiencing a 56 day delay in all study drugs (pomalidomide, dexamethasone, and 
elotuzumab )due to an adverse event(s) related to study  treatment must be discontinued from 
Revised Protocol No.: 01
Date: 11-Nov-[ADDRESS_215492] immediately  notify  the BMS Medical 
Monitor/designee of this event . In most cases, the study  drug will be permanently  discontinued in 
an appropriate manner. If the investigator determines a possible favorable benefit/risk ratio that 
warrants continuation of study  drug, a discussion between the investigator and the BMS Medical 
Monitor/designee must occur.
All subjects who discontinue study  drug should comply  with protocol specified follow -up 
procedures as outlined in Table 5.1-3. The only exception to this requirement is when a subject 
withdraws consent for all study  proce dures or loses the abilit y to consent freel y (ie, is imprisoned 
or involuntarily  incarcerated for the treatment of either a ps ychiatric or ph ysical illness).
If study  drug is discontinued prior to the subject’s completion of the study , the reason for the 
discontinuation must be documented in the subject’s medical records and entered on the 
appropriate case report form (CRF) page.
3.[ADDRESS_215493] .
3.6.1 Withdrawal of Consent
Subjects should be encouraged to continue participation in the trial until the laboratory  definition 
of disease progression is met (Appendix 6). Subjects who discontinue study therapy before 
progression (eg, due to toxicity) should be encouraged to allow the necessary laboratory 
results (eg, M-protein data, sFLC data. radiologic data, calcium results) to be collected 
until disease progression criteria are fulfilled, even ifthe subject ison subsequent therapy 
(seeSection 8.3.1
). Central laboratory  assessments are preferred; however assessments may also 
be completed locall y. Local lab data can be obtained by [CONTACT_748]’ local health care provider 
or the site staff. Site staff will enter local lab data into the CRF/database. Withdrawal of consent 
should be minimized because:
1.The subject in this trial who discontinues study  therap y before progression will most likely  
be followed by a healthc are provider locall y or at the site via routine standard of care 
assessments (ie, monthly  M-protein data, calcium, etc) and
Revised Protocol No.: 01
Date: 11-Nov-[ADDRESS_215494] the BMS Medical Monitor/study  director prior to:
1.starting a subject on another my eloma regimen or 
2. performing the end of treatment visit for progression
Subjects who request to discontinue study  drug will remain in the study  and must continue 
protocol specified follow -up procedures. The only exception to this is when a subject specifically 
withdraws consent for any further contact [CONTACT_35859]/her or persons previously  authorized by 
[CONTACT_20439]. Subjects should notify  the investigator of the decision to 
withdraw consent from future follow -up in writing , whenever possible. The withdrawal of 
consent should be explained in detail in the medical records by  [CONTACT_182462]:
1.Study  medication but subject is willing to continue to perform visits for PFS follow -up. 
2.Study  medication and study  visits for PFS but agrees to provide the results of future 
myeloma assessments from another site/local site.
3.Study  treatments and results from another site/local sites, but agrees to be contact[CONTACT_182463] -up.
4.Study  treatments and results from another site/local sites, and does not agree to be contact[CONTACT_182464] -up.
In the event that vital status (whether the subject is alive or dead) is being measured, publicly 
available information should be used to determine vital status only as appropriatel y directed in 
accordance with local law
3.6.[ADDRESS_215495]’s medical records. If it is determined that the 
subject has died , the site will use permissible local methods to obtain the date and cause of death. 
If investigator’s use of third- party representative to assist in the follow -up portion of the study  
has been included in the subject’s informed consent, then the investig ator may use a 
Sponsor -retained third- party  representative to assist site staff with obtaining subject’s contact 
[CONTACT_35864] -up portion of the 
study . The site staff and representative will consult publicly  available sources, such as public 
health registries, obituary  listings, and databases, in order to obtain updated contact [CONTACT_3031]. 
Revised Protocol No.: 01
Date: 11-Nov-[ADDRESS_215496]’s medical 
records
4 STUDY DRUG
All protocol -specified investigational and non -investigational products are considered study  drug
Revised Protocol No.: 01
Date: 11-Nov-2015 46
2.0
930082867
Clinical Protocol CA204125
BMS -901608 elotuzumab
Table 4 -1: Study Drugs for CA204125 
Product Description / 
Class and Dosage FormPotency IMP/Non -IMP Blinded or Open 
LabelPackaging / 
AppearanceStorage Conditions
(per label)
Elotuzumab Pow der for 
Solution for Infusion400 mg/vial IMP Open Label20 mL Vial/ Sterile, 
white to off -white, 
preservative -free, 
lyophilized cakeStore at 2C - 8C
Dexamethasone Tablets2 mg and 4 mg & 
various strengthsNon-IMP NAVarious packing 
configurationsRefer to label on 
container or package 
insert / summary of 
product characteristics
Dexamethasone Solution4 mg/mL, 8 mg/mL & 
various strengthsNon-IMP NAVarious packing 
configurationsRefer to label on 
container or package 
insert / summary of 
product characteristics
Pomalidomide Capsules1 mg, 2 mg, 3 mg and 4 
mgNon-IMP Open labelVarious packing 
configurationsRefer to label on 
container or package 
insert 
Dexamethasone tablets and solution for IV infusion may be obtained by [CONTACT_182465]’s standard prescribing procedures. 
Pomalidomide (Pomaly st®
) may be supplied b y BMS centrally  or thr ough site standard prescribing procedure.
Revised Protocol No.: 01
Date: 11-Nov-[ADDRESS_215497] in some regions, is 
defined a pharmaceutical form of an active substance or placebo being tested or used as a 
reference in a clinical study , including products alread y with a marketing authorization but used 
or assembled (formulated or packaged) differently  than the authorized form, or used for an 
unauthorized indication, or when used to gain further information about the authorized form.
The investigational product should be stored in a secure area according to local regulations. It is 
the responsibility  of the investigator to ensure that investigational product is only dispensed to
study  subjects. The investigational product must be dispensed only from official study  sites by 
[CONTACT_20443]. 
In this protocol, investigational product is: Elotuzumab powder for solution for infusion.
4.1.[ADDRESS_215498]’s weight (kg) by 10 mg/kgin Cycles 1 and 2 (20 mg/kg for Cycle 3and 
beyond). The subject’s predose weight on Day 1 of each cycle will be used to calculate the dose 
for each cycle. Each dose should be infused as per instructions in Appendix 5. The infusion start 
and stop time will be recorded in the CRF. If the infusion is stopped mid-session for any reason, 
the stop/start time must be recorded together with an explanation.
4.[ADDRESS_215499](s) are: Pomalidomide (Pomaly st) capsules 1mg, 
2mg, 3 mg, and 4 mg, dexamethasone tablets and concentrate for solution for IV infusion, or 
products used for Elotuzumab premedication (Section [IP_ADDRESS]) or thromboproph ylaxis 
(Section 3.4.1).
4.2.[ADDRESS_215500] not get pregnant: (1) for at 
least 4 weeks before starting pomalidomide, (2) while taking pomalidomide, (3) during any 
interruptions in pomalidomide treatment and (4) for at least [ADDRESS_215501] dose of 
pomalidomide. Furthermore, subjects taking pomalidomide should refrain from donating blood 
(until at least 90 day s) or sperm (until a t least 180 days) after last dose of pomalidomide. 
Because of this potential toxicity  and to avoid fetal exposure to pomalidomide, pomalidomide is 
only available under a special restricted distribution program. Each risk management program is 
country  or region specific . Under these programs, only prescribers and pharmacists registered 
Revised Protocol No.: 01
Date: 11-Nov-[ADDRESS_215502] be registered into the local, mandatory pomalidomide risk 
management program or follow the Pomalidomide Pregnancy  Risk Prevention Plan, and be 
willing and able to comply with allrequirements.
Please see the US package insert/SmPC for additional information for prescribing to female 
subjects and male subjects about this restricted distribution program.
Subjects should not break, chew or open the capsules. Pomalidomide should be taken without 
food (at least 2 hours before or 2 hours after a meal). Only enough pomalidomide for one cycle 
of therap y will be supplied to the patient each cycle in accordance with the local pomalidomide 
risk management program or the Pomalidomide Pregnancy  Risk Prevention Plan.
WOCBP must have negative pregnancy testing and use contraception methods before initiating 
pomalidomide.
The trade name [CONTACT_182483]. In such cases, refer to country 
trade name.
4.2.[ADDRESS_215503] characteristics (SmPC). See Table 
[IP_ADDRESS]-[ADDRESS_215504] storage manager should ensure that the study  drug is stored in accordance with the 
environmental conditions (temperature, light, and humidity ) as determined by [CONTACT_20444]. If concerns 
regarding the quality  or appearance of the study  drug arise, do not dispense the study  drug and 
contact [CONTACT_20445].
The investigator (or assigned designee, ie, study  pharmacist) will dispense the proper number of 
each strength tablet to the subject to satisfy  dosing requirements until the subject’s next visit. The 
subject must be instructed to return all unused study  medications in the provided packaging at 
each subsequent visit.
Procedures for proper handling and disposal of anticancer drugs should be considered.
Study  drug not supplied by  [CONTACT_53972].
Revised Protocol No.: 01
Date: 11-Nov-[ADDRESS_215505] documentation (whether supplied by [CONTACT_20447]) must be maintained 
that includes all processes required to ensure drug is accuratel y administered. This includes 
documentation of drug storage, administration and, as applicable, storage temperatures, 
reconst itution, and use of required processes (eg, required diluents, administration sets).
Procedures for proper handling and disposal of anticancer drugs should be considered
 
 
 
 
 
 
 
  
 
 
 
Revised Protocol No.: 01
Date: 11-Nov-2015 50
2.0
930082867

Clinical Protocol CA204125
BMS -901608 elotuzumab
 
 
   
   
 
 
 
 
 
Revised Protocol No.: 01
Date: 11-Nov-2015 51
2.0
930082867

Clinical Protocol CA204125
BMS -901608 elotuzumab
Revised Protocol No.: 01
Date: 11-Nov-2015 52
2.0
930082867

Clinical Protocol CA204125
BMS -901608 elotuzumab
Revised Protocol No.: 01
Date: 11-Nov-2015 53
2.0
930082867

Clinical Protocol CA204125
BMS -901608 elotuzumab
4.5.2 Guidelines for Elotuzumab Infusion in Subjects with Infusion Reactions
[IP_ADDRESS] Grade 1 Infusion Reaction
For Grade 1 elotuzumab infusion- related reactions, by [CONTACT_108], do not require intervention. 
However, increased monitoring is recommend ed.
[IP_ADDRESS] Grade 2 Infusion Reaction
Infusion reactions during the elotuzumab infusion : For a Grade [ADDRESS_215506] should be treated as clinicall y 
indicated with one or more of the following medications or interventions: antiemetics, 
antihistamines, analgesics, corticosteroids, leukotriene inhibitors, oxygen inhalation, 
epi[INVESTIGATOR_238], bronchodilators, or other supportive measures as indicated. Subjects with a Grade 4 
elotuzumab infusion reaction, see Section [IP_ADDRESS].
For Grade 2 or 3 infusion reactions, once the elotuzumab infusion- related reaction has resolved 
to Grade 1, the infusion can be restarted at 0.5 mL/minute. If symptoms do not recur after 
30minutes, the infusion rate may be increased in a stepwise fashion starting at a rate per 
investigator’s discretion, and increasing up to a rate per investigator’s discretion, up to a 
maximum of 5 mL /minute . 
Subjects who experience an infusion reaction require vital signs to be monitored every  
30minutes for [ADDRESS_215507]’s signs and symptoms. The infusion can be 
reattempted at the next protocol defined infusion time point at the investigator’s discretion with 
additional premedication as described in Table [IP_ADDRESS] -1.
Infusion reactions after the completion of elotuzumab infusion : Should a Grade2infusion 
reaction occur following completion of an elotuzumab infusion, the subject should be treated as
above .
Elotuzumab infusions on subsequent weeks after a prior Grade 2 or 3 infusion reaction : 
Subjects with a prior Grade [ADDRESS_215508] the subsequent 
infusion started at 0.5 mL/min. The infusion rate may be escalated in a stepwise fashion 
(0.5mL/minute every  30minutes) to a maximum of 5 mL/minute on that day. If no Grade2
infusion reaction occurs, the next infusion may beincreased in a stepwise fashion starting at a 
rate per investigators’ discretion, and up to a maximum of 5mL/minute .If tolerated, all 
subsequent infusions may start at a rate per investigator’s discretion, up to a maximum rate of 
5ml/minute.
Contact [CONTACT_22951] M onitor with any  questions regarding elotuzumab infusion rate escalation. 
[IP_ADDRESS] Grade 4 Infusion Reaction
Acute symptoms should be managed as described in Section [IP_ADDRESS]. Elotuzumab must be 
permanentl y discontinued. Subjects may continue with pomalidomide and dexamethasone per 
protocol.
Revised Protocol No.: 01
Date: 11-Nov-2015 54
2.0
930082867
Clinical Protocol CA204125
BMS -901608 elotuzumab
4.5.3 Dose Delay, Interruption, or Discontinuation, All Subjects
If the dose of one drug in the regimen (ie, pomalidomide, dexamethasone, or elotuzumab) is 
delay ed,interrupted, or discontinued, the treatment with the other drugs may continue as 
scheduled. However, if dexamethasone is delay ed or discontinued discuss ongoing elotuzumab 
administration with the medical monitor. Also see Section 3.5for delay s in study  drugs.
Each cycle is 28 days. While dose delay s or interruptions are permitted, the start of each cycle 
cannot be delay ed and is fixed (ie, anchored) relative to Cycle [ADDRESS_215509] is unable to start Cycle (X)until 3 days after the anchored start date, all assessments 
should be recorded on Cycle (X)Day 3. The following cycle should begin on Day 1(not Day 3)
of Cycle (X+1) .Missed doses should be skipped, not delay ed, if not given within the allowed 
window.
Subjects may continue on study  therap y even if components of the study  therap y must be 
discontin ued. For example, a subject on pomalidomide and dexamethasone may continue on 
study  therap y even if dexamethasone must be discontinued for an adverse event. Likewise, a 
subject on the elotuzumab arm may continue on study  therap y if elotuzumab must be 
discontinued for an adverse event or other reason. Subjects are considered still on study  therap y 
even if they  continue solely  on pomalidomide or dexamethasone.
Please consult the BMS Medical Monitor or any questions regarding dose interruption or study  
Revised Protocol No.: 01
Date: 11-Nov-[ADDRESS_215510]’s regular dosing time, to take pomalidomide as soon as the 
subject remembers. If it has been more than [ADDRESS_215511] be skipped. Subjects should 
not take 2 doses at the same time
4.5.4 Recommended Dose Reduction
The criteria presented in this section for dose modification of dexameth asone and pomalidomide 
are meant as general guidelines. They  are based on current US standards of clinical practice. 
Local standards may differ and may be followed. Dose modification may occur in the setting of 
lower grade toxicity  if the investigator, in consultation with the Medical Monitor/Sponsor, 
believes that it is in the interest of subject safet y.
[IP_ADDRESS] Elotuzumab
No dose reduction is allowed for elotuzumab.
[IP_ADDRESS] Dexamethasone
Dexamethasone dose reductions for toxicity must be performed as clinically  indicated. 
Recommended management is described in Table [IP_ADDRESS] -1and Table [IP_ADDRESS] -2Deviations to the 
recommended dose reductions are allowed based on the clinical judgment of the investigator.
Table [IP_ADDRESS]-1: Dexamethasone Dose Reductions
CTCAE 
CategoryAdverse Event Treatm ent Adjust ment
Gastrointestinal Dyspepsia, gastric or duodenal 
ulcer, gastritis
Grade 1 - 2 
(requiring medical management)Treat w ith a proton pump inhibitor.
If symptoms persist despi[INVESTIGATOR_64330], decrease by 
1dose level.
Grade 3 
(requiring hospi[INVESTIGATOR_78947])Hold dexamethasone until symptoms are adequately 
controlled. Reduce by [ADDRESS_215512] despi[INVESTIGATOR_64330], reduce t o dose 
level -3 (dose w ithheld).
Acute pancreatitis Reduce to dose level -3(dose withheld).
Cardiovascular Edema
Grade 3 (limiting function and 
unresponsive to therapy or 
anasarca)Use diuretics as needed, and decrease dexamethasone by 
1dose level. If edema persists despi[INVESTIGATOR_64330], 
decrease by [CONTACT_182466].
Neurology Confusion or Mood alteration 
Grade 2 (interfering with 
function interfering with 
activities of daily living)Hold dexamethasone until symptoms resolve.
Decrease by [ADDRESS_215513] despi[INVESTIGATOR_64330], decrease by 
[CONTACT_182466].
Revised Protocol No.: 01
Date: 11-Nov-2015 56
2.0
930082867
Clinical Protocol CA204125
BMS -901608 elotuzumab
Table [IP_ADDRESS]-1: Dexamethasone Dose Reductions
CTCAE 
CategoryAdverse Event Treatm ent Adjust ment
Musculoskeletal Muscle weakness 
Grade 2 (symptomatic and 
interfering with function 
interfering with activities of 
daily living)Hold dose until muscle weakness is Grade 1.
Decrease dexamethasone by 1 dose level and resume.
If weakness persists despi[INVESTIGATOR_64330], decrease by 
[CONTACT_182466].
Metabolic Hyperglycemia
Grade 3 or higherTreat w ith insulin or oral hypoglycemics as needed. If 
uncontrolled despi[INVESTIGATOR_64330], decrease by 1 dose 
level until glucose levels are satisfactory.
Constitutional Insomnia Grade 2 Decrease by 1 dose level and resume.
Dose reduction for persistent Grade 2 or Grade 3 AEs believed to be related to dexamethasone 
and not listed above are permitted. Dose reductions should follow the guidance in Table [IP_ADDRESS]-
1and Table [IP_ADDRESS] -2.
For subjects receiving elotuzumab, regardless of dexamethasone dose reduction, at least 8mg of 
the weekl y dexamethasone dose must be administered IV as part of the premedication for 
elotuzumab with the remainder of the weekl y dexamethasone dose administered orally  as 
described in Section 4.5.[ADDRESS_215514] 
discontinue dexamethasone due to dose limiting toxicity .
On day s without elotuzumab, no IV dexamethasone should be administered.
Table [IP_ADDRESS]-2: Dexamethasone Dose Levels
Dose Level Reducing Dexamethasone on
Weeks with ElotuzumabReducing Dexamethasone on
Weeks Without Elotuzumab
PO IV PO IV
0 75 years old -28 mg 8 mg 75 years old -40 mg
N/A
> 75 years old - 8mg > 75 years old -20 m g
-1 75 years old -12 mg 8 mg 75 years old -20 mg
N/A
> 75 years old - 2mg > 75 years old -12 m g
-2 75 years old -0 mg 8 mg 75 years old -12 mg
N/A
> 75 years old -0 mg > 75 years old -8 mg
-3 [ADDRESS_215515] 
Medical 
Monitor75 years old -0 mg
N/A> 75 years old -0 mg > 75 years old -0 mg
Revised Protocol No.: 01
Date: 11-Nov-2015 57
2.0
930082867
Clinical Protocol CA204125
BMS -901608 elotuzumab
[IP_ADDRESS] Pomalidomide
Below are the recommended dose adjustments for the management of thrombocy topenia and 
neutropenia judged by [CONTACT_182467]. Information in Table 
[IP_ADDRESS]-1 and Table [IP_ADDRESS]-2 is based on pomalidomide prescribing information, which contains 
additional guidance on pomalidomide dosing4344.
Table [IP_ADDRESS]-1: Treating Thrombocytopenia Related to Pomalido mide
When Platelet Count: Recommended Course:
Fall to < 25,000 per mm3Interrupt pomalidomide treatment, follow 
Com plete Blood Count weekly.
Return to > 50,000 per mm3Resume pomalidomide at 3 mg daily
For each subsequent drop < 25,000 mm3Interrupt pomalidomide treatment
Return to 50,000 mm3Resume pomalidomide at 1 mg less than previous 
dose
Table [IP_ADDRESS]-2: Treating Neutropenia Related to Pomalidomide
When Neutrophil Count: Recommended Course:
Fall to < 500 per mm3or febrile neutropenia (fever 
38.5oC and ANC < 1,000 mm3)Interrupt pomalidomide treatment, follow 
Com plete Blood Count weekly.
ANC returns to 1000 per mm3Resume pomalidomide at 3 mg daily
For each subsequent drop < 500 mm3Interrupt pomalidomide treatment
Return to 1000 mm3Resume pomalidomide at [ADDRESS_215516] management.
If necessary  to co-administer strong inhibitors of CYP1A2 in the presence of strong inhibitors of 
CYP3A4 and P -glycoprotein, consider reducing pomalidomide dose by  50% .43,44
4.6 Blinding/Unblinding
Not applicable.
4.[ADDRESS_215517]’s medical record. For those medications taken at home 
(POdexamethasone and pomalidomide), subjects will be provided with a medication diary  in 
which to record study  drug doses and will be instructed to bring this diary  and study  drug 
containers to clinic visits.
Revised Protocol No.: 01
Date: 11-Nov-2015 58
2.0
930082867
Clinical Protocol CA204125
BMS -901608 elotuzumab
4.8 Destruction and Return of Study Drug
4.8.1 Destruction of Study Drug
For this study , study  drugs (those supplied by [CONTACT_52240]) such as 
partially  used study  drug containers, vials and s yringes may be destroy ed on site. 
Any unused study  drugs can only be destro yed after being inspected and reconciled by [CONTACT_52241] y, or to meet local regulations (eg, cytotoxics or biologics). 
On-site destruction is allowed provided the following minimal standards are met:
On-site disposal practices must not expose humans to risks from th e drug.
On-site disposal practices and procedures are in agreement with applicable laws and 
regulations, including any  special requirements for controlled or hazardous substances.
Written procedures for on-site disposal are available and followed. The procedures must be 
filed with the site’s SOPs and a cop y provided to BMS upon request.
Records are maintained that allow for traceability  of each container, including the date 
disposed of, quantity  disposed, and identification of the person disposing the conta iners. The 
method of disposal, ie, incinerator, licensed sanitary  landfill, or licensed waste disposal 
vendor must be documented. 
Accountability  and disposal records are complete, up-to-date, and available for the Monitor 
to review throughout the clinical trial period.
If conditions for destruction cannot be met the responsible BMS Study  Monitor will make 
arrangements for return of study  drug.
It is the investigator’s responsibility  to arrange for disposal of all empty  containers, provided that 
procedures for proper disposal have been established according to applicable federal, state, local, 
and institutional guidelines and procedures, and provided that appropriate records of disposal are 
kept.
4.9 Return of Study Drug
If study  drug will not be destro yed upon completion or termination of the study , all unused 
and/or partially  used study  drug that was supplied by [CONTACT_20458]. The return 
of study  drug will be arranged by  [CONTACT_52242]. 
It is the investigator’s responsibility  to arrange for disposal of all empty  containers, provided that 
procedures for proper disposal have been established according to applicable federal, state, local, 
and institutional guidelines and procedures, and provided that appropriate records of disposa l are 
kept. 
4.10 Retained Samples for Bioavailability  / Bioequivalence
Not applicable.
Revised Protocol No.: 01
Date: 11-Nov-2015 59
2.0
930082867
Clinical Protocol CA204125
BMS -901608 elotuzumab
Revised Protocol No.: 01
Date: 11-Nov-2015 60
2.0
Approved
930082867
2.0
v

Clinical Protocol CA204125
BMS -901608 elotuzumab
Revised Protocol No.: 01
Date: 11-Nov-2015 61
2.0
Approved
930082867
2.0
v

Clinical Protocol CA204125
BMS -901608 elotuzumab
Revised Protocol No.: 01
Date: 11-Nov-2015 62
2.0
Approved
930082867
2.0
v

Clinical Protocol CA204125
BMS -901608 elotuzumab
Revised Protocol No.: 01
Date: 11-Nov-2015 63
2.0
Approved
930082867
2.0
v

Clinical Protocol CA204125
BMS -901608 elotuzumab
Revised Protocol No.: 01
Date: 11-Nov-2015 64
2.0
Approved
930082867
2.0
v

Clinical Protocol CA204125
BMS -901608 elotuzumab
Revised Protocol No.: 01
Date: 11-Nov-2015 65
2.0
Approved
930082867
2.0
v

Clinical Protocol CA204125
BMS -901608 elotuzumab
Revised Protocol No.: 01
Date: 11-Nov-2015 66
2.0
Approved
930082867
2.0
v

Clinical Protocol CA204125
BMS -901608 elotuzumab
Revised Protocol No.: 01
Date: 11-Nov-2015 67
2.0
Approved
930082867
2.0
v

Clinical Protocol CA204125
BMS -901608 elotuzumab
Revised Protocol No.: 01
Date: 11-Nov-2015 68
2.0
Approved
930082867
2.0
v

Clinical Protocol CA204125
BMS -901608 elotuzumab
Date: 11-Nov-2015 69
2.0
Approved
930082867
2.0
v

Clinical Protocol CA204125
BMS -901608 elotuzumab
Date: 11-Nov-2015 70
2.0
Approved
930082867
2.0
v

Clinical Protocol CA204125
BMS -901608 elotuzumab
Revised Protocol No.: 01
Date: 11-Nov-2015 71
2.0
Approved
930082867
2.0
v

Clinical Protocol CA204125
BMS -901608 elotuzumab
Revised Protocol No.: 01
Date: 11-Nov-2015 72
2.0
Approved
930082867
2.0
v

Clinical Protocol CA204125
BMS -901608 elotuzumab
Revised Protocol No.: 01
Date: 11-Nov-2015 73
2.0
Approved
930082867
2.0
v

Clinical Protocol CA204125
BMS -901608 elotuzumab
Revised Protocol No.: 01
Date: 11-Nov-2015 74
2.0
Approved
930082867
2.0
v

Clinical Protocol CA204125
BMS -901608 elotuzumab
Revised Protocol No.: 01
Date: 11-Nov-2015 75
2.0
Approved
930082867
2.0
v

Clinical Protocol CA204125
BMS -901608 elotuzumab
5.1.1 Retesting During Screening Period
Retesting of laboratory  parameters and/or other assessments within the Screening period will be 
permitted (in addition to any  parameters that require a confirmatory  value).
Any new result will override the previous result ( ie, the most current result prior to starting study 
drug) and is the value by [CONTACT_182468], as it represents the subject’s 
most current, clinical state.
Laboratory  parameters and/or assessments that are included in Table 5.1 -1, Screening Procedural 
Outline may be repeated in an effort to find all possible well-qualified subjects. Consultation 
with the Medical Monitor may be needed to identify  whether repeat testing of any particular 
parameter is clinicall y relevant.
5.2 Study Materials
The following will be distributed to sites for use in this study :
NCI CTCAE booklets version 3.0
Elotuzumab I nvestigator Brochure
Pomalidomide (Pomaly st) Package Insert
Site Manual for operation of IVRS
Subject Dosing Diary
Subject Quality  of Life Questionnaires 
Serious Adverse Event (SAE) Case R eport Form (CRF) pages
Pregnancy  Surveillance Forms
5.[ADDRESS_215518] of care; 
however, the data for these assessments should remain in the subject’s medical record and should 
not be provided to BMS, unless specificall y requested from the Sponsor. Safet y assessments 
must be done prior to dosing. The local safety  labs (complete blood count, chemistry  panel) and 
procedures may be collected or performed up to [ADDRESS_215519] be submitted to BMS.
All subjects will be assessed for safet y. Safety  evaluations include assessments of AEs, clinical 
laboratory  tests (hematology , chemistry ), vital sign measurements, and physical examination 
with assessment of ECOG PS. Investigators are responsible for monitoring the safet y of subjects 
who have entered this study  and for alerting the Sponsor to any  event that seems unusual, even if 
this event may be considered an unanticipated benefit to the subject. The investigator is 
responsible for appropriate medical care of subjects during the stud y.
Revised Protocol No.: 01
Date: 11-Nov-[ADDRESS_215520] medical/clinical judgment.
5.3.2 Vital Signs, Physical Measurements, and Physical Examination
Vital signs (body temperature, seated blood pressure and heart rate) will be recorded as outlined 
in Table 5.1-1, Table 5.1-[ADDRESS_215521] additional vital signs as follows: 
Prior to pre- medication administration
Prior to the start of the elotuzumab infusion
Thirty  minutes after the start of infusion
At the end of the infusion
For Cycles 1 and 2: Thirty  minutes and [ADDRESS_215522] completion of the elotuzumab 
infusion.
For C ycle 3 and beyond: post infusion vital signs will be measured at 30 minutes.
Subjects who experience a Grade [ADDRESS_215523]-treatment 
visits. A targeted physical examination may be performed by a qualified professional guided by 
[CONTACT_4921]’s observations and/or subject complaints on new or changed conditions, sy mptoms, 
or concerns. Targeted physical exam includes assessment of heart, lung, and abdomen.
5.3.3 Performance Status
Performance assessment will be performed as indicated in Table 5.1-1, Table 5.1-2 and Table 
5.1-3 using ECOG performance scale and criteria as described in Appendix 2. The assessment 
should be completed prior to any  study -related procedures, treatment or clinician assessment.
5.3.4 Cardiac Asse ssments 
A MUGA scan or 2-dimensional echocardiogram and electrocardiogram (ECG) will be 
performed at screening within 28 day s of randomization .
5.3.5 Laboratory Assessments for Safety
Laboratory  assessments for safet y will be performed at local laboratories. Safety laboratory 
assessments are listed in Table 5.3.5 -1.
Revised Protocol No.: 01
Date: 11-Nov-2015 77
2.0
930082867
Clinical Protocol CA204125
BMS -901608 elotuzumab
Table 5.3.5 -1: Safety Laboratory Assessments
Safety Laboratory Assessments
Screening as outlined in Table 
5.1-1Within 14 days of 
randomizationStudy Visits as outlined in
Table 5.1 -2and Table 5.1-3
Serum Hematology
CBC X X
Differential (absolute counts : 
neutrophils, lymphocytes, 
monocytes, basophils, eosinophils)X X
Platelets X X
Serum Chemistry
Sodium X X
Potassium X X
Chloride X X
Carbon Dioxide or BicarbonateaX X
Albumin X X
Alkaline Phosphatase X X
ALT (SGPT) X X
AST (SGOT) X X
Total Bilirubin X X
Direct Bilirubi nbX
Lactate Dehydrogenase X X
BUN (or Urea) X X
Creatinine X X
Glucose X X
Calcium X X
Total Protein X X
Magnesium X X
Pregnancy Test
Urine or Serum Pregnancy X (2 tests: one 10 -14 days prior to 
the start of study drug and one 
within 24 hours prior to the start of 
study drug)X
aTo be done in sites where this is a standard part of the chemistry panel. In sites where testing for CO2/HCO3 is 
not standard, the test is optional
bOnly required for subjects with Gilbert’s Syndrome. See Section 3.3.2
Revised Protocol No.: 01
Date: 11-Nov-2015 78
2.0
930082867
Clinical Protocol CA204125
BMS -901608 elotuzumab
5.4 Efficacy  Assessments
Efficacy  endpoints will bebased on analysis of serum and urine electrophoresis (SPEP and 
UPEP), sFLC (for those with sFLC disease only), corrected calcium (serum calcium and serum 
albumin), imaging and bone marrow assessments, all at predefined intervals as specified in Table 
5.1-1, Table 5.1-2 and Table 5.1-3. Assessments done at local labs versus central labs are 
indicated in Table 5.1-1, Table 5.1-2, Table 5.1-3, and Table 5.4.2-1. Assessments for SPEP , 
UPEP and sFLCwill be based on central lab results, whereas assessments of bone marrow, bone 
lesions, extramedullary  plasmacy tomas, and corrected calcium will be based on local analysis at 
the site.
5.4.1 Primary Efficacy Assessment
Response criteria inAppendix 632,33will be used for the efficacy  analysis. For the purposes of 
this study , all subjects’ tumor assessments by [CONTACT_182469] ( SPEP M protein and 
UPEP M protein quantification, correcte d calcium (calcium and albumin), and serum free light 
chain) should be re-evaluated per the protocol -stated frequency  relative to the date of first dose 
of study  drug until disease progression based on Appendix 6, irrespective of dose delay s or 
treatment cycle. If subject does not have documented disease progression as defined in 
Appendix 6at the time of study drug discontinu ation, then tumor assessments must 
continue tobe performed according to the same schedule described above until disease 
progression even if a subsequent anti-myeloma treatment is initiated prior to disease 
progression. Subjects will be followed every 12 weeks , or more frequently ,after disease 
progression for survival , subsequent myeloma therap y, and development of second primar y 
malignancy .
All efficacy  laboratory  assessments ( SPEP, UPEP, serum/urine immunofixation, and sFLC) 
should be done through the central laboratory , except corrected calcium (serum calcium and 
serum albumin), and bone marrow assessments for plasma cell percen tage and light chain 
restriction (clonality  by [CONTACT_182470] ). All bone marrow aspi[INVESTIGATOR_182444] . For any SPEP, UPEP, or sFLC assessment performed 
locally , in lieu of a central lab assessment, (ie, if the subject cannot complete a visit at the study  
site), M protein absolute quantification (eg,g/dL or g/L) or sFLC (eg,mg/L or mg/dL)must be 
performed. Any laboratory  samples analyzed locally , including forefficacy , must be entered on 
the appropriate CRF/eC RFas requested by [CONTACT_182471] .
5.4.[ADDRESS_215524] is discontinued from study  therap y and has started new myeloma 
therap y.Confirmation of PR is required on 2 consecutive assessments for Serum, Urine and 
sFLC.
Revised Protocol No.: 01
Date: 11-Nov-2015 79
2.0
930082867
Clinical Protocol CA204125
BMS -901608 elotuzumab
1)Serum :SPEP for M protein quantification, total serum protein, serum immunofixation, and 
quantitative immunoglobulin assay .
a.Serum Immunofixation is required at baseline and to confirm CR regardless of whether 
measurable M -protein was present at baseline.
b.Subjects with measurable disease inSPEP will be assessed for response based on SPEP 
and not by  [CONTACT_182472] .
c.Subjects with measurable disease in both SPEP and UPEP will be assessed for response 
based on these two tests and not by  [CONTACT_182472] .
d. All other serum tests will be followed at each tumor assessment.
2)Serum free light chain (sFLC) : 
a.Subjects without measurable serum M- protein (ie, < 0.5 g/dL (5 g/L) ) or urine M- protein 
(ie,<200 mg (0.2 g) per 24 hours) and considered oligosecretory  must have sFLC 
assessed at each cy cle until until progression.
b.Serum must be collected at screening and time of serum and urine IFE negativity  to 
confirm CR and be sent to the central lab for sFLC analy sis.This measurement is 
required to assess for sCR
3)Urine : 24-hour urine collection for M protein quantification, urinary light chains, and 
immunofixation. 24-hour urine must be collected with each cycle for all subjects .
a.Urine Immunofixation is required atbaseline and to confirm CR, regardless of whether 
measurable M -protein was present at baseline.
b.All other urine tests will be followed at each tumor asse ssment. 
4)Bone marrow aspi[INVESTIGATOR_1516]/biopsy :
Table 5.4.2 -1: Bone Marrow Samples
Sample Local Laboratory Central Laboratory
Aspi[INVESTIGATOR_337] 1) Samples required at the follow ing times 
to evaluate percentage plasma cells:
a) Screening (within 35 days of 
randomization ) 
b) When subject is immunofixation 
negative in both serum and urine 
(second bone marrow sample not 
required for confirmation) 
i) In addition, evaluate flow cytometry 
to assess plasma cell clonality 
(ie,lambda and kappa IHC or flow 
cytometry to assess lig ht chain 
restriction.
c) At tim e of suspected disease 
progression , if needed 
(seeSection 5.4.4 ) to assess PD in 
subjects whose myeloma become 
nonsecretory.
Evaluation of percentage of plasma cells 
should be performed locally per a) Screening (within 35 days of randomization
i) Genetic assessments (FISH) should be 
performed by [CONTACT_93493] a 
fresh bone marrow  sample. How ever, if a 
new bone marrow  sample collection is not 
feasible and if this assessment was 
performed locally within the [ADDRESS_215525] BMS 
medical monitor in these cases.
b) Aspi[INVESTIGATOR_182445] (section 5.6.1 ).
Revised Protocol No.: 01
Date: 11-Nov-2015 80
2.0
930082867
Clinical Protocol CA204125
BMS -901608 elotuzumab
Table 5.4.2 -1: Bone Marrow Samples
Sample Local Laboratory Central Laboratory
institution standard practice; 
Plasma cell percentage and light chain 
restriction assessments are required. If 
not available, IHC can be performed on 
bone marrow  core biopsy.
Biopsy Not required by [CONTACT_182473][INVESTIGATOR_182446] (at any time point above) is no t 
available due to a dry tap or due to 
laboratory preferences of the local 
pathologist
5)Serum Corrected Calcium : Serum corrected calcium should be collected with each cycle 
for all subjects until disease progression. 
Corrected Calcium, mg/dL = (0.8 x [Normal Albumin, g/dL  -Subject’s Albumin, g/dL ] + Serum 
Ca, mg/dL
5.4.3 Imaging Assessments for Myeloma
[IP_ADDRESS] Skeletal Survey
Skeletal survey , by [CONTACT_182474] y, for metastatic disease will be performed within 
28days ofrandomization in all subjects. Skeletal survey  will be performed on study  if clinically  
indicated (development of compression fracture does not exclude response) .Use of conventional 
or low dose CT scan (ie, of the spi[INVESTIGATOR_050]) or MRI bone survey  is acceptable. If imaging is performed 
on treatment for assessment of progression, the site must use the same modality  of imaging as 
used in screening. The number and location of skeletal lesions and whether they are lytic should 
be recorded on the eCRF. On treatment survey  should record whether there is an increase in the 
number or size of ly tic lesions.
[IP_ADDRESS] Assessment of Extramedullary Plasmacytoma
Computed tomograph y or MRI should be performed at screening, if clinically  indicated or if 
patient had a previous extr amedullary  or bone plasmacy toma. To minimize unnecessary  radiation 
in myeloma subjects where progression is primarily  based on serum and urine M-protein, on 
study  assessme nts should only be performed if clinically  indicated (ie, pain, concern for disease
progression), whether or not present at baseline, and at the time of CR/sCR assessment.
A sum of the products of the longest diameters and longest perpendicular diameter for all 
measurable lesions will be calculated at screening. This sum will be used as the reference for on 
study  assessments b y which to characterize the objective tumor response.
Revised Protocol No.: 01
Date: 11-Nov-[ADDRESS_215526] and MRI  should be performed with contiguous cuts of 10mm or less or with 
cuts of 5 (or 10) mm if spi[INVESTIGATOR_182447]. Imaging- based evaluation is preferred to 
evaluation by [CONTACT_12148]. Evaluati on by [CONTACT_13190] x-ray is less preferable than CT or MRI, 
and should only be used for well-defined lesions surrounded by [CONTACT_6776]. Clinical 
examination is only acceptable when lesions are superficial, such as a skin nodule or palpable 
lymph node. Skin lesions must be documented by a photograph with a ruler. Ultrasound is not 
acceptable for documentation of measurable disease.
Duplicate copi[INVESTIGATOR_182448] b y the Sponsor upon reque st.
Measurable disease are lesions that can be accuratel y measured in [ADDRESS_215527] be [ADDRESS_215528] scanning or [ADDRESS_215529] scanning or MRI. The minimum diameter size should be at leas t twice the 
slice thickness.
Non-measurable disease are all other lesions (or sites of disease), including those that are too 
small (ie, do not meet above criteria), occur within a previousl y irradiated area (unless they are 
documented as new lesions since the completion of radiation therap y), bone lesions, 
leptomeningeal disease, ascites, pleural or pericardial effusion (exception for effusions 
documented by [CONTACT_182475]), 
lymphangitis cutis/pulmonis, abdominal masses that are not pathologically/cytologicall y 
confirmed and followed by  [CONTACT_15218], and cy stic lesions.
5.4.4 Definitions of Response and Progression Criteria
See Appendix 6 for definitions of response and progression. All criteria are derived from 
IMWG46,47,48, except for minor (minimal) response, which is derived from EBMT. All response 
categories require 2 consecutive assessments made before initiation of any  new therap y.
5.5 Pharmacokinetic A ssessments
Blood samples for pharmacokinetic (PK)assessment will be drawn according to the PK 
sampling schedule provided in Table 5.5.1-1. Development of anti-drug antibodies (ADA) w ill 
be evaluated in all subjects receiving elotuzumab at specified time points as noted in Table 5.5.[ADDRESS_215530] the actual time of sample collection, even if this deviates from the 
protocol specified time.
Revised Protocol No.: 01
Date: 11-Nov-2015 82
2.0
930082867
Clinical Protocol CA204125
BMS -901608 elotuzumab
5.5.1 Anti-Drug Antibody (ADA)Assessments 
Development of Anti- Drug elotuzumab Antibodies (ADA) will be evaluated in subjects 
receiving elotuzumab at specified time points as noted in Table 5.5.1-1.
Table 5.5.1 -1: PK and ADA Sampling Schedule
Cycle NumberStudy 
DayTime (Event) PK CollectionaADA Collectiona
1 1 0 H (pre -dose) X X
[ADDRESS_215531] -end of infusion X
8 0 H (pre -dose) X
[ADDRESS_215532] -end of infusion X
15 0 H (pre -dose) X
22 0 H (pre -dose) X
[ADDRESS_215533] -end of infusion X
2 1 0 H (pre -dose) X X
[ADDRESS_215534] -end of infusion X
22 0 H (pre -dose) X
[ADDRESS_215535] -end of infusion X
3 1 0 H (pre -dose) X X
[ADDRESS_215536] -end of infusion X
4 1 0 H (pre -dose) X X
5 1 0 H (pre -dose) X X
6 1 0 H (pre -dose) X X
7 1 0 H (pre -dose) X X
[ADDRESS_215537] Cycle 
after Cycle 7 (ie 
Cycle 10, 13...etc)1 0 H (pre -dose) X X
End of Study / DiscontinuationbX X
30-Day Follow -UpbX X
[ADDRESS_215538] PK and ADA 
samples on the day (predose) that elotuzumab is restarted (noting the actual time of collection and dosing), and 
then continue following the schedule in Table 5.5.[ADDRESS_215539] remains on study drug(s), PK and ADA samples will be collected 
at: the day of the last elotuzumab dose, [ADDRESS_215540] 
elotuzumab dose
Revised Protocol No.: 01
Date: 11-Nov-2015 83
2.0
930082867
Clinical Protocol CA204125
BMS -901608 elotuzumab
5.5.2 Pharmacogenomic/Pharmacogenetic Assessments
Genetic assessment (FISH) of myeloma cells will be performed by a central laboratory  on the 
fresh bone marrow, during the screening period. If a fresh aspi[INVESTIGATOR_182449], but local 
genetic assessment has been performed since completing the last regimen, butprior to entering 
this study , these results must be entered into the CRF/eCRF. This assessment is considered to be 
standard of care for myeloma. Contact [CONTACT_182476]. Assessment may 
include but not be limited to FISH anal yses in Section 5.6. In addition, potential biomarkers of 
resistance or sensitivity to pomalidomide or elotuzumab may be explored in these tumor 
samples.
5.6.1 Bone Marrow Aspi[INVESTIGATOR_182450]:
Bone marrow aspi[INVESTIGATOR_182451] a Central Lab:
1)Cytometry  of:
a)Plasma cell (PC) subsets :  Evaluation of, but not limited to SLAMF7 (target of 
elotuzumab) and PD-L1 on enumerated CD138+/CD38+PCs. PC subsets will be furthe r 
subdivided into normal and aberrant (malignant) based on differential expression of 
CD19 and CD56. 
b)Lym phoid and myeloid subsets :  will be enumerated and evaluated for expression of but 
not limited to SLAMF7 and PD-1. In addition to the absolute lymphocy te count, 
enumeration and percentage of cell subsets will be determined by [CONTACT_182477], naïve and memory  T cell subsets, Tregcells, 
Th17 cells, MDSCs, and pDCs.
2)Gene expression : CD138 magnetic separation and enrichment of CD138+ (plasma cells) and 
CD138- negative (which includes ly mphocy tes) cells and RNAseq of PCs and ly mphocy tes in 
the bone marrow microenvironment. 
3)Protein analysis (marrow): Following separation of CD138+ and CD138 -cell cellular 
fractions from the bone marrow aspi[INVESTIGATOR_337] (see “Gene expression analysis”), the soluble 
(non-cellular) fraction will be assessed for proteins, including but not limited to soluble 
SLAMF7 (sSLAMF7) and potentially  immune regulators such as cy tokines/chemokines.
4)Fluorescence in-situ hybridization (FISH): bone marrow aspi[INVESTIGATOR_182452]: 
t(4;14), t(14;16), t(11;14), t(6;14), t(14;20), 1q gains/amp, del(17p), del(1p), and del(13). 
FISH analysis will be limited to bone marrow aspi[INVESTIGATOR_182453] (mandated) and 
at EOT (if available). 
5)Molecular minimum residual disease (MRD) assessment by  [CONTACT_182478] ® ClonoSI GHT assay .
6)Cytometry  MRD: using a portion of the bone marrow sample collected at time of CR/sCR.
Revised Protocol No.: 01
Date: 11-Nov-2015 84
2.0
930082867

Clinical Protocol CA204125
BMS -901608 elotuzumab
5.6.2 Peripheral Blood Samples: 
Peripheral Blood samples for Biomarker Assessments will be evaluated at a Central Lab:
1)Lym phoid and m yeloid subsets : (same population as with marrow).
2)Molecular (MRD) whole b lood assessment by  [CONTACT_182478]ClonoSI GHT assay .
3)Protein analysis (serum) : Assessment of soluble proteins in circulation that include but are 
not limited to sSL AMF7 and potentially  immune regulators such as cy tokines/chemokines.
4)Fc-γR polymorphisms : for geno typi[INVESTIGATOR_182454] (minimally  CD16a and CD32a) 
and other host genes that may be related to regulators of immune response and anti-tumor 
activity .
5)Gene Expression Profiling : gene expression levels and changes (along with gene networks or 
pathway s) to better understand the complex nature of the immune response.
5.7 Outcomes Research A ssessments
5.7.1 Patient -reported Outcomes (PRO) Assessments
To assess the impact of treatment on patient- reported outcomes, two questionnaires will be used:
1)M.D. Anderson Sympto m Inventory  Multiple Myeloma module MDASI -MM (Appendix 4), 
which measures sy mptoms.
2)EuroQol Group’s EQ-5D (Appendix 5), which measures utilities, and is a preference -based 
measure of health status.
Questionnaires will be administered to all subjects per the schedule in Table 5.1-1, Table 5.1-2
and Table 5.1-3. 
All questionnaires will be administered at (1) baseline (prior to randomization); (2) on Day 1 of 
each 4 week treatment cycle; (3) at the end of treatment or study  withdrawal; (4) at each survival 
follow -up at the post treatment phase of the study  via telephone. Traditional telephone 
communication between research staff and patient, or automated interactive voice response 
(IVR) system may reduce the burden of missing data in monitoring patient reported outcomes 
while they are away  from the clinical sites. EQ-5D has been validated in paper, telephone 
interview, as well as IVR formats. Telephone interview scripts in local languages, detailed 
training and instructions will be provided to field staff administering the questionnaire.
Subjects should fill out the questionnaire prior to any study-related procedures, treatment or 
clinical assessment in order to prevent these variables from influencing PRO results. PRO 
instruments are provided as part of the CRF. Questionnaires will be provided in the subject’s 
prefer red language.
Revised Protocol No.: 01
Date: 11-Nov-2015 85
2.0
930082867
Clinical Protocol CA204125
BMS -901608 elotuzumab
M. D. Anderson Symptom Inventory (MDASI) is reliable, valid instrument that was designed 
for ease of administration and that asks patients to rate 13 symptoms (“core” items) and 
6symptom -related interference items that are common across cancer types and treatments. The 
multiple myeloma module of the MDASI (MDASI -MM) is a site-specific module that augments 
the 19 core MDASI sy mptom and interference items with additional items identified as unique to 
multiple myeloma. Along with the core MDASI’ s 13 symptom items and 6interference items, 
the MDASI -MM also assesses 7 multiple myeloma -specific symptom items: bone aches, muscle 
weakness, sore mouth/throat, rash, difficult y concentrating, constipation, and diarrhea.
EuroQol Group’s EQ -5D:
Because oncology  therapi[INVESTIGATOR_182455] y affect a patient’s quality  of life, a 
common methodological approach is used to quantify  this effect by “quality  adjusting” survival 
in comparative treatment arms. The result, quality  adjusted life years (QALYs ), is a measure of 
both the length and quality  of life and is used as a measure of benefit in cost-utility  analysis. 
Unfortunatel y, general PRO instruments such as the EORTC QLQ C30 are not designed to 
measure subject preferences (or utilities) in a way that is suitable for calculating QALYs. 
Therefore, a separate validated instrument, in this case the EuroQol EQ 5D, will be used to 
quantify  utilities to calculate QALYs for cost utility  analy ses.
The EQ 5D is a 5-item questionnaire and a “thermometer” visua l analogue scale ranging from 
0(worst imaginable health state) to 100 (best imaginable health state) that will be administered 
at the same intervals as the other PRO instruments, including at the Screening Visit to assess the 
comparability  of the groups a t study  initiation. The time referent is “today” for this instrument.
Enhancing Compliance
It is necessary  to implement specific measures to ensure optimal compliance in PRO data 
collection. Both staff and patients will be provided with the necessary  training and resources for 
optimal data collection at the appropriate times. Collaboration between the study  coordinator, the 
data center responsible for the day to day administration of the study  and the individual 
investigators can lead to organizational impr ovements. More specific measures will be targeted 
at the patient, the physician and the data manager or the research nurse, though there is 
considerable overlap.
Missing Data
If a questionnaire is missing during the acceptable time delay , a reason should be recorded 
(eg,refusal, nurse forgot, etc.), and the patient should be contact[CONTACT_182479] a reply  paid envelope. An acceptable time delay or “window” during 
which the questionnaire must be completed is [ADDRESS_215541] treatment, to ensure evaluation of short -term toxicity  and response. During 
follow up for EQ-5D, a wider window (3 weeks) would be acceptable after the first two 
post-treatment visits.
Revised Protocol No.: 01
Date: 11-Nov-2015 86
2.0
930082867
Clinical Protocol CA204125
BMS -901608 elotuzumab
5.7.2 Healthcare Resour ce Utilization
During the study , healthcare resource utilization (HRU) data associated with medical encounters 
related to disease or treatments or both will be collected for all subjects. Specificall y, HRU is 
evaluated based on the number of medical care encounters such as hospi[INVESTIGATOR_182456], outpatient visits, diagnostic tests and procedures, and concomitant medications. HRU 
data will be collected from all sites. The medical resource utilization data will be utilized to 
conduct economic analyses.
5.[ADDRESS_215542] be reported in the CRF
6 ADVERSE EVENTS
An Adverse Event (AE) is defined as any new untow ard medical occurrence or worsening of a 
preexisting medical condition in a clinical investigation subject administered study  drug and that 
does not necessarily  have a causal relationship with this treatment. An AE can therefore be any 
unfavorable and unintended sign (such as an abnormal laboratory  finding), symptom, or disease 
temporally  associated with the use of study  drug, whether or not considered related to the study 
drug.
The causal relationship to study  drug is determined by a physician and should be used to assess 
all adverse events (AE). The causal relationship can be one of the following:
Related: There is a reasonable causal relationship between study  drug administration and the AE.
Not related: There is not a reasonable causal relationship betwe en study  drug administration and 
the AE. 
The term "reasonable causal relationship" means there is evidence to suggest a causal 
relationship. 
Adverse events can be spontaneously  reported or elicited during open -ended questioning, 
examination, or evaluatio n of a subject. (In order to prevent reporting bias, subjects should not be 
questioned regarding the specific occurrence of one or more AEs.)
6.1 Serious A dverse Events
A Serious Adverse Event (SAE) is any  untoward medical occurrence that at an y dose: 
results in death
is life -threatening (defined as an event in which the subject was at risk of death at the time of 
the event; it does not refer to an event which hypothetically  might have caused death if it 
were more severe)
Revised Protocol No.: 01
Date: 11-Nov-2015 87
2.0
930082867
Clinical Protocol CA204125
BMS -901608 elotuzumab
requires inpatient hospi[INVESTIGATOR_312] 
(seeNOTE below)
results in persistent or significant disability /incapacity
is a congenital anomal y/birth defect 
is an important medical event (defined as a medical event(s) that may not be immediatel y 
life-threatening or result in death or hospi[INVESTIGATOR_313], based upon appropriate medical and 
scientific judgment, may jeopardize the subject or may require intervention [eg, medical, 
surgical] to prevent one of the other serious outcomes listed in the definit ion above.) 
Examples of such events include, but are not limited to, intensive treatment in an emergency 
room or at home for allergic bronchospasm; blood dyscrasias or convulsions that do not 
result in hospi[INVESTIGATOR_059].) Potential drug induced liver injury  (DILI) is also considered an 
important medical event. (See Section 6.6for the definition of potential DILI.)
Suspected transmission of an infectious agent (eg, pathogenic or nonpathogenic) via the study  
drug is an SAE. 
Although pregnancy , overdose, cancer, and potential drug induced liver injury  (DILI) are not 
alway s serious by [CONTACT_52252], these events must be handled as SAEs. 
(See Section 6.1.1 for reporting pregnancies).
Any component of a study  endpoint that is considered related to study  therap y (eg, death is an 
endpoint, if death occurred due to anaphy laxis, anaphy laxis must be reported) should be reported 
as SAE (see Section 6.1.1 for reporting details).
NOTE: 
The following hospi[INVESTIGATOR_102412] : 
a visit to the emergency  room or other hospi[INVESTIGATOR_20347] < 24 hours, that does not result in 
admission (unless considered an important medical or life- threatening event)
elective surgery , planned prior to signing consent
admissions as per protocol for a planned medical/surgical procedure
routine health assessment requiring admission for baseline/trending of health status 
(eg,routine colonoscop y)
medical/surgical admission other than to remed y ill health and planned prior to entry  into the 
study . Appropriate documentation is required in these cases
admission encountered for another life circumstance that carries no bearing on health status 
and requires no medical/surgical intervention (eg, lack of housing, economic inadequacy , 
caregiver respi[INVESTIGATOR_040], fa mily circumstances, administrative reason).
Admission for administration of anticancer therapy  in the absence of any  other SAEs (applies 
to oncology  protocols)
Revised Protocol No.: 01
Date: 11-Nov-2015 88
2.0
930082867
Clinical Protocol CA204125
BMS -901608 elotuzumab
6.1.1 Serious Adverse Event Collection and Reporting
Sections 5.6.1 and 5.6.2 in the Investigator Brochure (IB) represent the Reference Safet y 
Information to determine expectedness of serious adverse events for expedited reporting. 
Following the subject’s written consent to participate in the study , all SAEs, whether related or 
not related to study  drug, must be collected, including those thought to be associated with 
protocol -specified procedures. All SAEs must be collected that occur during the screening period 
and within 60days of discontinuation of dosing or within [ADDRESS_215543] be completed for an y event where doubt exists regarding its seriousness. 
If the investigator believes that an SAE is not related to study  drug, but is potentially  related to 
the conditions of the study  (such as withdrawal of previous therapy  or a complic ation of a study  
procedure), the relationship must be specified in the narrative section of the SAE Report Form.
SAEs, whether related or not related to study  drug, and pregnancies must be reported to BMS 
(ordesignee) within [ADDRESS_215544] be recorded on the SAE 
Report Form; pregnancies on a Pregnancy  Surveillance Form (electronic or paper forms). The 
preferred method for SAE data reporting collection is through the eCRF. The paper 
SAE/pregnancy  surveillance forms are only  intended as a back -up option when the eCRF system 
is not functioning. In this case, the paper forms are to be transmitted via email or confirmed 
facsimile (fax) transmission to:
SAE Email Address: Refer to Contact [CONTACT_20491].
SAE Facsimile Number:  Re fer to Contact [CONTACT_20491].
For studies capturing SAEs through electronic data capture (EDC), electronic submission is the 
required method for reporting. In the event the electronic system is unavailable for transmission, 
paper forms must be used and submitted immediately .When paper forms are used, the original 
paper forms are to remain on site.
SAE Telephone Contact (required for SAE and pregnancy  reporting): Refer to Contact 
[CONTACT_20491].
If only  limited information is initially  available, follo w-up reports are required. (Note: Follow -up 
SAE reports must include the same investigator term(s) initially  reported.) 
If an ongoing SAE changes in its intensity  or relationship to study  drug or if new information 
becomes available, the SAE report must be updated and submitted within 24 hours to BMS 
(ordesignee) using the same procedure used for transmitting the initial SAE report.
All SAEs must be followed to resolution or stabilization.
6.2 Nonserious A dverse Events
Anonserious adverse event is an AE not classified as serious.
Revised Protocol No.: 01
Date: 11-Nov-2015 89
2.0
930082867
Clinical Protocol CA204125
BMS -901608 elotuzumab
6.2.1 Nonserious Adverse Event Collection and Reporting
The collection of nonserious AE information should begin at initiation of study  drug. Nonserious 
AE information should also be collected from the start of a placebo lead-in period or other 
observational period intended to establish a baseline status for the subjects. 
Nonserious AEs should be followed to resolution or stabilization, or reported as SAEs if they 
become serious (see Section 6.1.1). Follow -up is also required for nonserious AEs that cause 
interruption or discontinuation of study  drug and for those present at the end of study  treatment 
as appropriate. All identified nonserious AEs must be recorded and described on the nonserious 
AE page of the CRF (paper or electronic). 
Completion of supplemental CRFs may be requested for AEs and/or laboratory  abnormalities 
that are reported/identified during the course of the study.
6.[ADDRESS_215545] result abnormalities should be captured on the nonserious AE CRF 
page or SAE Report Form (paper or electronic) as appropriate:
Any laboratory  test result that is clinically  significant or meets the definition of an SAE 
Any laboratory  test result abnormal ity that required the subject to have study  drug 
discontinued or interrupted
Any laboratory  test result abnormality  that required the subject to receive specific corrective 
therap y.
It is expected that wherever possible, the clinical rather than laboratory  term would be used by 
[CONTACT_9673] (eg, anemia versus low hemoglobin value).
6.[ADDRESS_215546] time 
to washout (90 days) plus one ovulatory  cycle (30 days) for a total of 120 days, or plus one 
spermatogenesis cycle (90 days) for a total of [ADDRESS_215547] immediately  notify  the BMS Medical Monitor/designee of this event and 
complete and forward a Pregnancy  Surveillance Form to BMS Designee within [ADDRESS_215548] cases, the study  drug will be permanently  discontinued in an appropriate manner 
(eg,dose tapering if necessary  for subject safet y).
In the rare event that the benefit of continuing study  drug is thought to outweigh the risk, after 
consultation with BMS, the pregnant subject may continue study  drug after a thorough 
discussion of benefits and risk with the subject 
Revised Protocol No.: 01
Date: 11-Nov-[ADDRESS_215549] unless contraindicated by [CONTACT_8663]  (eg, x-ray studies). Other appropriate pregnancy 
follow -up procedures should be considered if indicated.
The investigator must immediately  notify  the BMS (or designee) Medical Monitor of this event 
and complete and forward a Pregnancy Surveillance Form to BMS (or designee) within [ADDRESS_215550] be 
reported as an SAE (see Section 6.1.1 for reporti ng details).
6.6 Potential Drug Induced Liver Injur y (DILI)
Wherever possible, timely  confirmation of initial liver-related laboratory abnormalities should 
occur prior to the reporting of a potential DILI event. All occurrences of potential DILIs, 
meeting the defined criteria, must be reported as SAEs (see Section 6.1.1 for reporting details).
Potential drug induced liver injury  is defined as: 
1. AT (ALT or AST) elevation > 3 times upper limit of normal (ULN)
AND
2.Total bilirubin > [ADDRESS_215551], without initi al findings of cholestasis (elevated serum alkaline 
phosphatase)
AND
3.No other immediatel y apparent possible causes of AT elevation and hyperbilirubinemia, 
including, but not limited to, viral hepatitis, pre -existing chronic or acute liver disease, or th e 
administration of other drug(s) known to be hepatotoxic.
6.7 Other Safety  Considerations
Any significant worsening noted during interim or final physical examinations, 
electrocardiogram, x-ray filming, any other potential safet y assessment required or not required 
by [CONTACT_20492] a nonserious or serious AE, as appropriate, and reported 
accordingl y.
Revised Protocol No.: 01
Date: 11-Nov-2015 91
2.0
930082867
Clinical Protocol CA204125
BMS -901608 elotuzumab
Second primary  malignancies (SPMs) will be collected throughout the study  which includes 
assessments during survival follow -up. All SPMs that occur during the screening period and 
within 60 day s of discontinuation of dosing will be reported as an SAE regardless of relationship 
to study  drug. Additionally , any SPM that occurs after this timeframe and considered related to 
study  drug will be reported as an SAE. All other SPMs will be collected and reported on a 
separate CRF page.
7 DATA MONITORING COMM ITTEE 
Not applicable.
 
 
 
 
  
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Revised Protocol No.: 01
Date: 11-Nov-2015 92
2.0
930082867

Clinical Protocol CA204125
BMS -901608 elotuzumab
 
 
 
 
 
 
8.3 Endpoints
8.3.1 Primary Endpoint(s)
[IP_ADDRESS] Primary definition of PFS
PFS will be defined as the time, in months, from randomization to the date of the first 
documented tumor progression or death due to any cause. Clinical deterioration will not be 
considered progression. A subject who neither progresses nor dies will be censored on the date of 
their last tumor assessment. A subject who does not have any post-baseline tumor assessments 
and who has not died will be censored on the date at which they  were randomized.
[IP_ADDRESS] Secondary Definition of PFS: 
PFS will be analyzed after censoring patients who either received subsequent therapy  or had two 
or more missing tumor assessments prior to their disease progression or death. In this secondary 
definition, PFS will also be measured as the time in months from randomization to the date of the 
first documented tumor progression or death due to any cause, provided death does not occur 
more than 10 weeks (2 or more assessment visits) after the last tumor assessment. Clinical 
deterioration will not be considered progression.
The following censoring rules will be applied for this definition of PFS:
Subjects who receive secondary  anti-myeloma therapy  prior to documented progression will 
be censored on the date of the lastadequate tumor assessment prior to the initiation of the 
new therap y.
Subjects who have an event (documented progression or death) > 10 weeks (2assessment 
visits) after the last prior tumor assessment will be censored at the last adequate prior 
assessment.
Subjects who neither receive subsequent therap y prior to progression nor have a progression 
event will be censored at their last adequate tumor assessment.
Revised Protocol No.: 01
Date: 11-Nov-2015 93
2.0
930082867

Clinical Protocol CA204125
BMS -901608 elotuzumab
8.3.2 Secondary Endpoint(s)
[IP_ADDRESS] Objective response rate
Objective response rate is defined as the proportion of randomized subjects who achieve a best 
response of partial response (PR) or better using the criteria in Appendix 6 . 
[IP_ADDRESS] Overall survival
Overall survival is defined as the time from randomization to the date of death from any  cause. If 
a subject has not died, their survival time will be censored at the date of last contact (“last known 
alive date”). A subject will be censo red at the date of randomization if they  were randomized but 
had no follow -up. 
 
 
 
 
 
 
 
        
 
 
 
 
 
 
 
 
Revised Protocol No.: 01
Date: 11-Nov-2015 94
2.0
930082867

Clinical Protocol CA204125
BMS -901608 elotuzumab
 
 
[IP_ADDRESS] Secondary Efficacy Analysis
Objective response rate is a secondary  objective. A two-sided = 0.2 level 
Cochran -Mantel -Haenszel (CMH) test, stratified using the same factors as in PFS, will be used to 
compare the response rate between the treatment arms. The response rate, along with its exact 
two-sided 80% CI, will be computed within each treatment arm. A two-sided, 80% CI for 
difference of response rate between the treatment arms will also be computed. In addition, the 
two-sided 95% CI will also be computed.
Overall survival is another secondary  objective. It will be compared between arms using a 
stratified group sequential log-rank test procedure with a two-sided, =0.[ADDRESS_215552] a popula tion pharmacokinetic (PPK) analy sis. Results of PPK will be reported 
separately . Anti-drug antibodies will also be assessed.
 
 
 
 
 
 
 
Revised Protocol No.: 01
Date: 11-Nov-2015 95
2.0
930082867

Clinical Protocol CA204125
BMS -901608 elotuzumab
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revised Protocol No.: 01
Date: 11-Nov-[ADDRESS_215553] be discussed with, and be prepared by, BMS. The investigator should not implement any 
deviation or change to the protocol without prior review and docum ented approval/favorable 
opi[INVESTIGATOR_5698]/IEC of an amendment, except where necessary  to eliminate an immediate 
hazard(s) to stud y subjects. 
If a deviation or change to a protocol is implemented to eliminate an immediate hazard(s) prior 
to obtaining IRB/IEC approval/favorable opi[INVESTIGATOR_1649], as soon as possible the deviation or change 
will be submitted to:
IRB/IEC for review and approval/favorable opi[INVESTIGATOR_1649]
BMS
Regulatory  Authority (ies), if required by  [CONTACT_52264](s)/IEC(s) must be 
sent to BMS.
If an amendment substantially  alters the study  design or increases the potential risk to the 
subject: (1) the consent form must be revised and submitted to the IRB(s)/IEC(s) for review and 
approval/favorable opi[INVESTIGATOR_1649]; (2) the revised form must be used to obtain consent from subjects 
currentl y enrolled in the study  if they  are affected by  [CONTACT_29991]; and (3) the new form must 
be used to obtain consent from new subjects prior to enrollment.
If the revision is done via an administrative letter, investigators must inform their I RB(s)/IEC(s).
9.1.[ADDRESS_215554] ofthe study  with the investigator, and verify 
that the facilities remain acceptable. CRF pages and/or electronic files may serve as the source 
documents:  such as outcome assessments.
In addition, the study  may be evaluated by [CONTACT_182480], source documents, other study  files, and study  facilities. 
BMS audit reports will be kept confidential.
The investigator must notify  BMS promptly  of any inspections scheduled by [CONTACT_3527], and promptly forward copi[INVESTIGATOR_20350]. 
Revised Protocol No.: 01
Date: 11-Nov-2015 97
2.0
930082867
Clinical Protocol CA204125
BMS -901608 elotuzumab
[IP_ADDRESS] Source Documentation
The Investigator is responsible for ensuring that the source data are accurate, legible, 
contemporaneous, original and attributable, whether the data are hand -written on paper or 
entered electronically . If source data are created (first entered), modified, maintained, archived, 
retrieved, or transmitted electronicall y via computerized systems (and/or any other kind of 
electronic devices) as part of regulated clinical trial activities, such systems must be compliant 
with all applicable laws and regulations governing use of electronic records and/or electronic 
signatures. Such systems may include, but are not limited to, electronic medical/health records 
(EMRs/EHRs), adverse event tracking/reporting, protocol required assessments, and/or drug 
accountability  records).
When paper records from such systems are used in place of electronic format to perform 
regulated activities, such paper records should be certified copi[INVESTIGATOR_014]. A certified copy consists of a 
copy  of original information that has been verified, as indicated by a dated signature, as an exact 
copy  having all of the same attributes and information as the original. 
9.1.3 Investigational Site Training
Bristol -Myers Squibb will provide quality  investigational staff training prior to study  initiation. 
Training topi[INVESTIGATOR_20351]: GCP, AE reporting, study  details and 
procedure, electronic CRFs, study documentation, informed consent, and enrollment of WOCBP.
9.[ADDRESS_215555] BMS prior to destroy ing 
any records associated with the study .
BMS will notify  the investigator when the study records are no longer needed.
If the investigator withdraws from the study  (eg, relocation, retirement), the records shall be 
transferred to a mutually agreed upon designee (eg, another investigator, IRB). Notice of such 
transfer will be given in writing to BMS. 
9.2.[ADDRESS_215556] of study  drug 
(inventoried and dispensed) is maintained at the study  site to include investigational product and 
the following non-investigational product(s) pomalidomide and dexamethasone. Records or logs 
must comply  with applicable regulations and guidelines and should include:
amount received and placed in storage area
amount currentl y in storage area
label identification number or batch number 
amount dispensed to and returned b y each subject, including unique subject identifiers
Revised Protocol No.: 01
Date: 11-Nov-2015 98
2.0
930082867
Clinical Protocol CA204125
BMS -901608 elotuzumab
amount transferred to another ar ea/site for dispensing or storage
non-study  disposition (eg, lost, wasted) 
amount destroy ed at study  site, if applicable
amount returned to BMS
retain samples for bioavailability /bioequivalence, if applicable 
dates and initials of person responsible for Investigational Product dispensing/accountability , 
as per the Delegation of Authority  Form .
BMS will provide forms to facilitate inventory  control if the investigational site does not have an 
established sy stem that meets these requirements.
9.2.[ADDRESS_215557] safet y. CRFs may  be requested for AEs and/or laboratory  abnormalities 
that are reported or identified during the course of the study .
For sites using the BMS electronic data capture tool, electronic CRFs will be prepared for all 
data collection fields exc ept for fields specific to SAEs and pregnancy , which will be reported on 
the paper or electronic SAE form and Pregnancy  Surveillance form, respectively . Spaces may  be 
left blank only in those circumstances permitted by [CONTACT_3449]-specific CRF completion guideli nes 
provided b y BMS. 
The confidentiality  of records that could identify  subjects must be protected, respecting the 
privacy  and confidentiality  rules in accordance with the applicable regulatory  requirement(s).
The investigator will maintain a signature [CONTACT_182484]/or corrections on CRFs. 
The completed CRF, including any paper or electronic SAE/pregnancy  CRFs, must be promptl y 
reviewed, signed, and dated by [CONTACT_20510] a subinvestigator 
and who is delegated this task on the Delegation of Authority  Form .For electronic CRFs, review 
and approval/signature [CONTACT_52271] y through the BMS electronic data capture tool. 
The investigator must retain a copy of the CRFs including records of the changes and 
corrections.
Each individual electronically  signing electronic CRFs must meet BMS training requirements 
and must only access the BMS electronic data capture tool using the unique user account 
provided b y BMS. User accounts are not to be shared or reassigned to other individuals.
9.[ADDRESS_215558] be selected to sign the clinical study  report. 
Revised Protocol No.: 01
Date: 11-Nov-2015 99
2.0
930082867
Clinical Protocol CA204125
BMS -901608 elotuzumab
For this protocol, the Signatory  Investigator will be selected as appropriate based on the 
following criteria:
Subject recruitment (eg, among the top quartile of enrollers)
Involvement in trial design
Other criteria (as determined by  [CONTACT_2362])
The data collected during this study  are confidential andproprietary  to BMS. Any publications 
or abstracts arising from this study  must adhere to the publication requirements set forth in the 
clinical trial agreement (CTA) governing [Study  site or Investigator] participation in the study . 
These requirements include, but are not limited to, submitting proposed publications to BMS at 
the earliest practicable time prior to submission or presentation and otherwise within the time 
period set forth in the CTA.
Revised Protocol No.: 01
Date: 11-Nov-[ADDRESS_215559] 
chooses to forego complete abstinence.
Expanded definition Complete abstinence as defined as 
complete avoidance of heterosexual intercourse is an 
acceptable form of con traception for all study  drugs. This 
also means that abstinence is the preferred and usual lifesty le 
of the patient. This does not mean periodic abstinence 
(eg,calendar, ovulation, sy mptothermal, profession of 
abstinence for entry  into a clinical trial, p ost-ovulation 
methods) and withdrawal, which are not acceptable methods 
of contraception. Subjects who choose complete abstinence 
are not required to use a second method of contraception, but 
female subjects must continue to have pregnancy  tests. 
Acceptabl e alternate methods of highl y effective 
contraception must be discussed in the event that the subject 
chooses to forego complete abstinence
Revised Protocol No.: 01
Date: 11-Nov-[ADDRESS_215560] Complementary  Determining Regions
°C Celsius
CI Confidence Interval
CMH Cochran -Mantel -Haenszel
CMMC Circulating Multiple Myeloma Cells
CR Complete response
CRF Case Report Form
CrCl Creatinine Clearance
CS1 CD-[ADDRESS_215561] Computerized tomography
CTCAE Common Terminology  Criteria for Adverse Events
DILI Drug induced liver injury
DLT Dose -limiting toxicity
DMC Data monitoring committee
DVT Deep Vein Thrombosis
EBMT European Group for Blood and Bone Marrow Transplant
ECG Electrocardiogram
EORTC European Organization for Research and Treatment of Cancer
E-Pd Elotuzumab Pomalidomide (low dose) dexamethasone
EPO Erythropoietin
FSH Follicle -stimulating hormone
GCP Good Clinical Practice
G-CSF Granulocy te colony -stimulating factor
HCG Human Chorionic Gonadotropin
HR Hazard Ratio
Revised Protocol No.: 01
Date: 11-Nov-2015 102
2.0
930082867
Clinical Protocol CA204125
BMS -901608 elotuzumab
Term Definition
HRQoL Health Related Quality  of L ife
HRT Hormone replacement therap y
ICH International Council on Harmonization
IF Immunofixation
IHC Immunohistochemistry
IL-2 Interleukin 2
IMiDs Immune Modulatory  Drugs
IMWG International M yeloma Working Group
IRB/IEC Institutional Review Board/I ndependent Ethics Committee
IV Intravenous
ITT Intent -to-treat
NK Natural Killer
NKT Natural Killer T -Cells
Ld Lenalidomide (low -dose) dexamethasone
LD Lenalidomide (high -dose) dexamethasone
LdE Lenalidomide, (low -dose) dexamethasone, elotuzumab
LPFV Last patient first visit
MDASI -MM MD Anderson S ymptom Inventory  Multiple My eloma Module
MGUS Monoclonal Gammopathy  of Undetermined Significance
MM Multiple My eloma
MR Minor (Minimal) Response
MRD Minimal Residual Disease
MRI Magnetic Resonance Imaging
MTD Maximum tolerated dose
NK Natural Killer 
NKT Natural Killer T -cell
ORR Objective Response Rate
OS Overall Survival
PBMC Peripheral blood mononuclear cells
Pd Pomalidomide (low dose) dexamethsone
Revised Protocol No.: 01
Date: 11-Nov-2015 103
2.0
930082867
Clinical Protocol CA204125
BMS -901608 elotuzumab
Term Definition
PFS Progression- free survival
PK Pharmacokinetic
PR Partial Response
rrMM relapsed refractory  Multiple My eloma
SAE Serious adverse event
sCR Stringent complete response
sMICA soluble major histocompatibility  complex class I  chain -related gene A
SLAMF7 Signaling Lymphocy te Activation Molecule family  7
SPM Second primary  malignancy
sSLAMF7 soluble SL AMF7
SMM Smolder ingMultiple Myeloma
WOCBP Women of childbearing potential
Revised Protocol No.: 01
Date: 11-Nov-2015 104
2.0
930082867
Clinical Protocol CA204125
BMS -901608 elotuzumab
APPENDIX 1 DEFINITION OF LINES OF THERA PY
Line of Therapy (from International Myeloma Working Group (Rajkumar, 2011)) is defined as 
one or more cycles of a planned treatment program . This may consist of one or more planned 
cycles of single -agent therap y or combinatio n therap y, as well as a sequence of treatments 
administered in a planned manner. For example, a planned treatment approach of induction 
therap y followed by [CONTACT_182481], followed by  [CONTACT_182482] . Each subsequent line of therapy starts when a planned course of therap y is 
modified to include other treatment agents (alone or in combination) as a result of disease 
progression, relapse, or toxicity . A new line of therap y also starts when a planned period of 
observation off therap y is interrupted b y a need for additional treatment for the disease.  
Revised Protocol No.: 01
Date: 11-Nov-2015 109
2.0
930082867